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Abstract
Background: After myocardial infarction (MI), fibrosis and an ongoing dysregulated
inflammatory response are associated with adverse cardiac remodeling. Fluorodeoxyglucose
(FDG) positron emission tomography (PET) is sensitive to inflammation provided
suppression protocols are implemented to restrict the uptake of glucose in myocytes.
Magnetic resonance imaging can be used to determine extracellular volume, a surrogate
measure of fibrosis. In some cases, patients present with markedly reduced flow in the setting
of a large infarct, i.e. microvascular obstruction, restricting the delivery of FDG and contrast
agents. To overcome this problem, a constant infusion was explored as an alternative to the
clinical standard bolus injection. This led to three objectives: a) comparison of the constant
infusion to the bolus injection in healthy canines, b) investigation of the potential of the
constant infusion to discriminate post-MI tissue types, and c) determination of the efficacy of
the suppression protocol and its effect on extracellular volume.
Methods: All imaging was done with a hybrid PET/MRI scanner. MRI images were used to
determine the regions of interest: remote, injured and obstructed myocardium. PET images
were used to determine inflammation. To compare the injection strategies, five healthy
canines were examined with all three. Subsequently, eight animals were imaged at baseline
and days 3, 7, 14, 21, and 42 post-MI using a 60-min infusion. Lastly, seven animals were
imaged at baseline and day 5 post-MI using a 150-min infusion. Forty minutes into the
infusion, suppression of glucose uptake in myocytes was started.
Results: No significant differences in terms of glucose metabolism and extracellular volume
were seen in healthy myocardium between the three injection strategies: bolus injection,
constant infusion and bolus followed by constant infusion, showing that a strategy involving
the constant infusion produced similar results as to those obtained with a bolus injection.
Following MI, a significant increase in extracellular volume was seen in remote tissue on
days 14 and 21, suggesting an inflammatory response. During the 150-min infusion,
suppression of myocardial glucose uptake had the unexpected result of reducing FDG uptake
in inflammatory cells within the infarcted area.
ii

Conclusion: This research showed the possibility of using a constant infusion of Gd-DTPA
and FDG to investigate inflammation within the entire myocardium. The finding that
suppression affected inflammatory cells highlights the need for tracers which do not rely on
myocardial glucose suppression.

Keywords
Myocardial Infarction, Heart Failure, Positron Emission Tomography, Magnetic Resonance
Imaging, Hybrid PET/MRI, Constant Infusion of Tracer
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Summary for Lay Audience
After a myocardial infarction, commonly referred to as heart attack, scar tissue and
inflammation develop within the injured area. The scar tissue can be imaged with MRI and
the inflammation with PET, provided injected contrast agents can reach the heart tissue.
Some patients present with an area of extremely low flow within the injured region,
unreachable with a clinically used bolus injection. A goal of my research is to test whether a
constant infusion can be used to get the PET tracer and contrast agent into the injured region
which is critical for imaging patient after a heart attack: if the PET tracer does not enter, there
is no way to measure inflammation. The first experiment compared bolus injection and
constant infusion in the normal healthy heart to establish if the results from these injection
strategies are the same. The second experiment applied this approach in a model of
myocardial infarction to determine if a constant infusion can measure inflammation and
scarring in the remote, injured and obstructed regions of the heart. Lastly, since the PET
imaging technique requires an infusion of fats to block the uptake of the PET tracer in normal
heart tissue, the efficacy of this approach was tested.
Methods: All imaging was done with a hybrid PET/MRI scanner. MRI images were used to
determine the regions of interest: remote, injured and obstructed myocardium. PET images
were used to determine inflammation. To visualize inflammation lipids were infused.
Results: No differences were seen between constant infusion and bolus injection in healthy
tissue. Findings from the second experiment suggested damage due to inflammation in
remote tissue at days 14 and 21 after the heart attack. The last experiment showed that the
suppression approach affected the injured region, suggesting that suppression measurement
of inflammation in infarcted tissue may be underestimated.
Conclusion: This research demonstrated the ability to use hybrid PET/MRI with a dual
contrast agent protocol to image inflammation in the myocardium. It also showed that remote
tissue may be damaged from a myocardial infarction and that the current approach of
suppression, necessary for inflammation imaging, may affect inflammatory cells, hindering
accurate quantification of inflammation.
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Preface
The first chapter in this thesis is adapted from a published review paper: Wilk B, Wisenberg
G, Dharmakumar R, Thiessen JD, Goldhawk DE, Prato FS. Hybrid PET/MR Imaging in
Myocardial Inflammation Post-Myocardial Infarction. J Nucl Cardiol 2019. 27(6):20832099. This chapter sets the groundwork for the rest of the thesis in terms of what has been
done in the field of imaging inflammation post-myocardial infarction and how current PET
and MRI techniques can be applied to complement each other. Also outlined are tracer and
contrast agent options to image different aspects of inflammation. In the following chapters,
the focus is on a combination of FDG and gadolinium-based contrast agent. The constant
infusion technique will be investigated to optimize tracer delivery and image all regions of
the heart rather than only the infarcted area.

xxiii

1

Chapter 1

1

Hybrid PET/MR Imaging of Myocardial Inflammation
Post-Myocardial Infarction

In this introductory chapter, I review the current and predict the future contributions that
hybrid PET/MRI technology can make toward advancing our understanding of
myocardial inflammation post-myocardial infarction. First, it is necessary to describe the
role of inflammatory cells post-MI, then the contributions that MRI has made to this
understanding. This is followed by explaining the contribution that PET has made. Then,
with this background on the separate contributions that MRI and PET can and, in the
future, could make, we introduce the technology of hybrid PET/MRI and explore how it
has, to date, and could, in the future, further our understanding of inflammation post-MI.
We explore the potential contributions of hybrid PET/MRI if we first treat hybrid
PET/MRI as more than a simple combination of PET and MRI. Rather, we suggest that
hybrid PET/MRI can be treated as a new convergent technology, where the PET aspect is
modified to the realities of MRI and the MRI modified to the realities of PET. We
investigate, under this convergent view of hybrid PET/MRI, biophysical explorations that
would result in new horizons in imaging inflammation post-MI. We conclude that fruitful
research would be the development of hybrid PET/MRI protocols including combining,
for the first time, concurrent simultaneous injections of a PET tracer and an MRI contrast
agent. In the research that follows (chapters 2 and 3) we first demonstrate that the novel
acquisition protocols and novel infusion methods provide valid, quantitative results. Then
in chapter 4, we explore this methodology to address the fundamental questions with
respect to cardiac imaging that in the past has not, and perhaps could not, be addressed if
a convergent approach of hybrid PET/MRI had not been used.

1.1

Introduction

Although early mortality in patients with acute myocardial infarction (AMI) has declined
by 75% over the past half century1, these patients still remain at risk for late adverse
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events and death2. Evidence suggests that infarct size3,4, extent of microvascular
obstruction within infarcted tissue5 and extent of iron precipitation6–8 following
hemorrhagic infarction are independent predictors of left ventricular remodeling postAMI, leading to heart failure. Furthermore, this remodeling is associated with additional
effects on myocardial tissue remote from the AMI caused by an ongoing dysregulated
pro-inflammatory process9,10. The target/substrate to be imaged in post-myocardial
infarction is predominantly inflammatory cells responding to aseptic injury. There is also
growing evidence that the presence of iron in the infarcted tissue following a
hemorrhagic infarct plays a further role in modulation of inflammation6,8.

1.1.1

Role of inflammatory cells

After AMI, pro-inflammatory processes stabilize the region of infarction with scar tissue
that strengthens the muscle to prevent the development of an aneurysm and reduce the
potential for sudden death from cardiac rupture11–13. Two cellular hallmarks of this proinflammatory stage include neutrophils14 (peaking within the first few hours to days postMI in humans and dogs) and classically-activated (M1) macrophages (peaking between 3
and 10 days post-MI in humans and dogs)6,15–20. The population of M1 macrophages is
primarily of myeloid origin, but may also include tissue resident macrophages within the
myocardium and those drawn from splenic reservoirs21–24. These are the dominant
inflammatory cell types responding to MI. The pro-inflammatory period is followed by
an anti-inflammatory stage where the predominant cellular hallmark is the recruitment of
alternatively-activated (M2) macrophages13. Note that M1 and M2 macrophages are a
simplification and the picture is more complex with in-between macrophage phenotypes
and the possibility for the polarization to change25,26. It has been suspected that
progression to heart failure post AMI is related to a sustained pro-inflammatory
response27,28. A sustained pro-inflammatory response may also have negative effects on
scar stability leading to cardiac rupture29.
Anti-inflammatory clinical trials have yielded mixed results30. If anti-inflammatory
therapies are given too early to reduce the “healing” inflammatory response, the patients
are at increased risk of aneurysm; if administered too late, there is an increased risk of
negative local and remote myocardial tissue remodeling. In order to develop effective
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therapies tailored to modify this dynamic process towards improved clinical outcomes, a
non-invasive cardiac imaging method is required to detect the differential time course,
post-AMI, of the inflammatory processes in three myocardial tissues: a) infarcted tissue
with microvascular obstruction (i.e. infarcted obstructed tissue, IOT), b) infarcted tissue
excluding the zone of microvascular obstruction (i.e. infarcted not obstructed tissue,
INOT) and c) myocardial tissue remote from the infarcted tissue (i.e. remote tissue, RT).
These tissues may have vastly different patterns and timing of the inflammatory response.
However, if the appropriate therapy could be tailored for each patient early in the
management and progression of the disease process, using noninvasive imaging to
differentiate between neutrophils, M1 and M2 macrophages, then we could optimize
therapy in real time, inform treatment and personalize care.
Given their divergent effects, non-invasive imaging that distinguishes between M1 and
M2 macrophages is critical and hence an understanding of the differences that could be
exploited for imaging is essential. Glucose uptake in M1 macrophages is approximately
twice that of M2 macrophages and phagocytic activity of M2 is approximately twice that
of M131,32. Also, macrophage phenotype may be distinguished based on iron handling, as
M1 exhibit an iron storage phenotype while M2 display an iron recycling phenotype33,34.
Macrophages are among the few mammalian cells to express the only recognized
mammalian iron export protein, ferroportin. Its activity is subject to regulation by the
endocrine hormone hepcidin, produced primarily in the liver in response to proinflammatory cytokines, like interleukin-6, and elevated levels of iron. Systemic
hepcidin-ferroportin interactions induce ferroportin degradation and interrupt iron
export35. In the dog, serum hepcidin levels rise within 4 to 6 days post-MI (unpublished
data from the laboratory of Dr. DE Goldhawk), facilitating the production of M1
macrophages and locally depriving the injured tissue of iron. In the canine model of
myocardial hemorrhage, Kali et al6 suggest that elevated iron stalls macrophage
progression from M1 to M2, consistent with the interaction of hepcidin and ferroportin.
This in turn may delay the evolution of M2 activities needed to stabilize the scar, like
fibroblast formation, and may also damage RT by prolonging the pro-inflammatory
activity of M1 macrophages.
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1.2 Magnetic Resonance Imaging (MRI) of myocardial
inflammation
Post-MI, MRI is an attractive modality to use due to its high spatial resolution, excellent
soft tissue contrast, and ability to mitigate and/or measure cardiac and respiratory motion.

1.2.1

Functional Imaging

The capability of MRI to acquire “cine” images of wall motion throughout the cardiac
cycle during breath holds has resulted in cardiac MRI becoming effectively the gold
standard for the quantitation of ejection fraction, end diastolic volumes and end systolic
volumes, all important in the definition of cardiac function with respect to progression
towards heart failure. The imaging of left ventricle wall strain showing wall fiber tracks
has not been as important. Although developed in the 1990s36 strain imaging has yet to
establish itself for discriminating INOT and IOT37. The imaging of smaller cardiac
structures such as those associated with the atria have been more difficult due to the
thinness of the atrial wall, approaching the resolution of MRI. Developments such as
phase contrast flow imaging, where the velocity of moving magnetic moments (flow) is
proportional to the phase shift38, and its successor, 4D Flow, have been helpful in
estimating effects of valve defects on regurgitant fraction in the ventricles39. Attempts to
apply 4D Flow to investigate effects of atrial fibrillation are in development40.

1.2.2

“Scar imaging”

It has been shown extensively that the distribution volume of gadolinium chelates such as
Gd-DTPA corresponds to the extracellular space in the myocardium. This is calculated as
the ratio of the concentration of Gd chelate in the myocardium divided by the
concentration in the blood, which is often referred to as the partition coefficient and
designated as λ. The volume of distribution can be calculated from λ if the hematocrit
(Hct) is known, i.e. Vd = λ x (1 – Hct). It has been shown in both humans and dogs that λ
in myocardial tissue post-MI increases from approximately 0.45 to 0.9 ml/g41–43. For a
hematocrit of 0.4, this would correspond to volumes of distribution going from 0.27 to
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0.54 ml/g. It has also been shown that a) this increase occurs within a few hours of
occlusion/reperfusion injury43, b) that it may be reduced when the post-MI injury has
become chronic43,44, c) it represents a marker of permanently damaged myocardium45, as
reversible injury such as stunning41 or hibernation46 does not increase λ substantially47
and d) given MRI’s spatial resolution, it allows the transmural extent of the infarct to be
determined48,49. Non-contrast-enhanced scar imaging approaches have also demonstrated
that scar following MI can be characterized on the basis of T1 mapping using modified
Look-Locker with balanced steady state free-precession readouts at 3.0 T50,51.

1.2.3

Edema imaging

The T2 relaxation rate increases in tissue containing an increase in extra-cellular water
i.e. edema, resulting in a hyperintense signal in T2-weighted MRI. The extent to which
edema correlates with the extent of inflammation post-MI still needs to be determined52.

1.2.4

Iron detection

T2*-weighted cardiac MR is effective in the detection and characterization of
infarction/reperfusion induced myocardial hemorrhage7,8,53. Histological study of canine
myocardial infarction has shown that persistent microvascular obstruction post-MI
culminates in the development of ferric iron oxide crystals, an increased proinflammatory burden and adverse remodeling6. A postulated mechanism is that the
conversion from M1 to M2 macrophages may be delayed by this iron crystal formation
leading to dysregulation of the inflammatory response and progression to heart failure
and/or an aneurysm at the site of infarction6. However, in vivo validation of this
hypothesis requires the non-invasive differential imaging of M1 and M2 macrophages at
the site of iron accumulation. Note that it has recently been shown in the P19 monocyte
cell line that extracellular iron concentration (25µM of ferric nitrate) reduces ferroportin
expression54. Quantitative susceptibility mapping (QSM) has also been used to determine
tissue iron content and relate this to patient outcome55.
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1.2.5

Myocardial blood flow

Myocardial blood flow is a major consideration when discussing myocardial
inflammation as it may play a major role in the degree and extent of the process.
Myocardial blood flow can be measured following a bolus injection of a gadolinium
chelate with transmural resolution56,57. However, complete heart coverage may not
always be possible and two bolus injections to account for signal saturation are often
employed58,59, increasing the amount of Gd-chelate that is needed though methods are
being developed to overcome these issues. Comparison to determinations using PET have
indicated the increased complexity of the use of Gd-chelates which have a much lower
extraction fraction compared to PET methods such as those using 13N-Ammonia or 15Owater60–62. It is important to note here that 13N-Ammonia enters and is trapped in living
cells while Gd-chelates are extracellular63.

1.2.6

BOLD MRI contrast

Blood oxygen level dependent (BOLD) contrast in MRI has been extensively applied for
the non-invasive study of the brain. Due to the decreased extraction fraction of oxygen
when blood flow increases, venous blood contains higher levels of oxyhemoglobin with a
corresponding decrease in the concentration of deoxyhemoglobin. When the venous
deoxyhemoglobin concentration falls, then T2* increases. Hence the BOLD effect is an
indication of the venous concentration of deoxyhemoglobin. Li et al64 have shown in
normal volunteers that following the administration of the hyperemic agent,
dipyridamole, with increased myocardial blood flow, there is an increase in T2* which is
consistent with a decrease in myocardial venous deoxyhemoglobin concentration as
myocardial oxygen supply exceeds demand64. In contrast, the administration of
dobutamine resulted in an increase in coronary blood flow but no significant change in
T2* consistent with a lack of change in myocardial venous deoxyhemoglobin
concentration which is interpreted as a balance between oxygen supply and demand. This
seminal work laid the foundation for future applications. However, not until recently has
the BOLD measurement in the myocardium been of sufficient accuracy to be used in
routine cardiac assessment. Recently, new MRI methods for the measurement of cardiac
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BOLD have shown considerable promise indicating a potential to assess myocardial
ischemia comparable with SPECT and PET methodologies65. As this has now been
demonstrated in a canine model of ischemia, clinical studies demonstrating feasibility are
needed.

1.2.7

Chemical exchange saturation transfer (CEST)

Chemical exchange saturation transfer (CEST) relies on the selective saturation and
exchange of protons from metabolites of interest to the free protons imaged with MRI66–
68

. CEST has been used to detect changes in protein concentration69, glutamate70,

creatine71, glycosaminoglycan and most notably pH (acidoCEST)72,73 and D-glucose
(glucoCEST)74–76 though it can be difficult to unravel changes in CEST signal from
changes in pH, T1, temperature and other metabolites77. To our knowledge, neither
glucoCEST nor acidoCEST have been attempted in the heart, although there would be
some utility for alternative measurements of perfusion and pH post-MI. Cardiac CEST
acquisitions are challenging, however, recent promising results suggest its utility for
measuring myocardial creatine kinase78–80 and hyaluronan synthesis81 post-MI.

1.2.8

Labeling Inflammatory Cells

Iron particles of magnetite are strong negative contrast agents attenuating the MRI signal
through the strong susceptibility induced by ferromagnetism. Using iron particles to label
cells has been investigated using two different approaches. In one, inflammatory cells are
isolated from blood lymphocytes, labeled with iron particles (such as superparamagnetic
iron oxide (SPIO) particles) and then re-injected82. In this scenario, detection of loss of
MRI signal within the myocardium signifies presence of labeled cells once the blood
background is reduced, and, provided the iron particles have not been released by dying
lymphocytes and either engulfed by other cells or lodged in the extracellular space. This
signal may also be confounded by endogenous iron due to hemorrhage. Although it has
been shown that, under optimal conditions, individual cells can be seen, quantitation of
label has proven challenging due to a) the difficulty in relating the magnitude of the loss
of MRI signal with the amount of iron particles83 and b) the dilution of the label as
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labeled cells proliferate. This effectively limits the quantitation of the number of cells.
Note that labeling cells with positive contrast (e.g. 19F) may overcome this issue but
dilutions due to proliferation cannot be overcome84–86.
In addition to phagocytic activity, monocytes and macrophages possess iron export
activity that is detectable by MRI. In the human THP-1 monocyte cell line, iron export
prevails regardless of extracellular iron concentration87. These cells display both
autocrine/paracrine regulation of ferroportin as well as the endocrine response to
hepcidin. In the multi-potent P19 cell line, extracellular iron stimulates iron export
through transcriptional regulation, whereas the presence of hepcidin knocks it back down
via post-translational modification35,54,88. Thus, processes governing the up and
downregulation of iron export co-exist and contribute an MR visible signal that will be
influenced by pro-inflammatory signaling through hepcidin, the inherent iron recycling
activity of M2 macrophages, and the iron released from SPIO degradation.
In the second approach, SPIO particles or perfluorocarbon agents are injected
intravenously, hypothesizing that macrophages will engulf them and allow their
detection. It has been shown in vitro that their engulfment rate in M2 macrophages is
approximately 50% greater than for M1 macrophages31. However, using this method, the
MRI signal will be related to the uptake of particles by both M1 and M2 macrophages,
making it difficult to determine the relative contribution of each cell population to the
signal change.
Hyperpolarized 13C-pyruvate is another option for imaging macrophages as the lactate
signal is increased in macrophages in vitro89. It has also been shown that rodents and pigs
exhibit a high lactate response in the infarcted region post-MI90.
MRI reporter genes that deliver strong contrast have been difficult to develop91. One of
the best approaches involves introducing genes from magnetotactic bacteria in
mammalian cells for the biosynthesis of membrane-enclosed SPIO-like particles called
magnetosomes92. The technology was initially attempted using single gene expression
systems93. If this technology could be implemented such that the concentration of iron
particles in mammalian cells were equal to that in magnetotactic bacteria, theoretical
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calculations indicate that as few as 3 cells could be detected in small animals and as few
as 2,600 cells in large animals and humans93. This would correspond to a major
breakthrough. For example, white blood cells from the peripheral circulation (e.g.
monocytes) could be isolated and transfected with the MR reporter gene expression
system, which could be programmed to produce magnetosome-like iron particles upon
promoter activation. For example, the receptor gene could be engineered to signal, by
production of iron particles, a molecular event involved in differentiation of the
monocyte into an M1 macrophage. One of the main obstacles remaining is the acceptance
of genetically modified cells for human use, although this strategy is now permitted in
some therapeutic applications94.

1.3

PET imaging post-myocardial infarction

Although there are a large number of PET probes for cardiac investigation that have been
developed, see Fig 1-1, clinical practice to date for use in post-MI patients has used only
a few95. PET imaging post-MI is most commonly done with 18F-FDG although
suppression of healthy myocyte glucose uptake is needed concurrent with flow tracers to
evaluate ischemia. However, other tracers that target translocator protein (TSPO)
receptors in inflammatory cells, such as 18F-GE180 which, while having potential for preclinical small animal imaging of macrophage activity, has been largely dismissed for
human imaging due to poor brain penetration96 or 18F-FEPPA97,98, may be used to target
macrophages specifically.

1.3.1

Glucose metabolism

Inflammation can be measured with 18F-FDG due to the increased presence of glucose
transporters on macrophages99. Due to this, uptake of glucose is upregulated in areas of
inflammation. The non-specificity of 18F-FDG for evaluating cardiac inflammation is,
however, compounded by uptake in normal myocytes which must be suppressed for
successful, unambiguous detection of inflammation. The failure, at times, to effectively
suppress that uptake by either dietary modification (high fat), overnight fasting and/or
heparin injection, may result in failure of the test. Five percent of the time this test fails
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even under the best diet and fasting protocols100. The reduced spatial resolution of 18FFDG PET compared to 3T MRI makes it difficult to uniquely identify 18F-FDG uptake in
the three tissue regions post MI: IOT, INOT and RT. Although in vivo cardiac imaging
reflects the significant uptake by inflammatory cells, it may not allow the distinction
between M1 and M2 inflammatory cells.
It has been shown in vitro that 18F-FDG uptake in M1 macrophages is greater than in M2
macrophages. Uptake in M1 macrophage is twice that of M2 when differentiated from the
human THP-1 monocyte cell line31. In contrast, when using primary monocytes from
human blood, the uptake of 18F-FDG in M1 macrophages is ten times greater than M2101.
This is further obscured as uptake of 18F-FDG by neutrophils and monocytes may be
similar to that of M1 macrophages. Although compartmental analysis allows the
quantitation of glucose metabolism in units of mmol per gram per minute, there has been
little or no attempt to evaluate quantitative 18F-FDG uptake post-MI in macrophages. The
upregulation of 18F-FDG metabolism in inflammatory cells must be very large for this to
be seen in infarcted tissue since the density of inflammatory cells in infarcted tissue
would be much lower than that of myocytes in normal and remote tissue. It is unknown at
this time if myocardial suppression of 18F-FDG uptake affects uptake of 18F-FDG in
inflammatory cells. However, work reported of 18F-FDG studies in cardiac sarcoidosis
indicates that if uptake is suppressed in inflammatory cells it is not sufficient to eliminate
the strong signal of inflammation102.

1.3.2

Blood flow

Historically, PET myocardial blood flow measurements have used 13N-Ammonia, 15O
water or 82Rb. At centers using PET/CT, 82Rb is often used since it does not require an
on-site cyclotron, as opposed to 13N-Ammonia (10 min half-life) and 15O-water (2 min
half-life). However, the 82Rb positron range reduces effective spatial resolution and, to
date, no manufacturer of 82Rb/82Sr generators has produced an MR-compatible system. In
this context, 13N-Ammonia is attractive for cyclotron-equipped sites and it has both high
first pass extraction fraction and good retention characteristics103. However, the 10minute half-life makes stress/rest studies expensive. More development of a repeat
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injection strategy would lower costs substantially by greatly reducing the length of the
exam104. Alternatively, 18F-flurpiridaz is attractive due to its very high extraction and
retention characteristics, but the cost of the tracer may negatively impact its
implementation. Additionally, the long half-life makes it difficult to conduct stress/rest
exams during a single imaging session as the traditional approach requires waiting for the
tracer to have decayed between the stress and the rest scans. New single-scan dualinjection protocols have significantly cut down the required time for Furpriridaz
perfusion imaging105. Whereas the measurement of blood flow reserve is important in the
scenario of stable coronary disease, its value post-MI has not been established, perhaps
due to the difficulty of combining two 13N-Ammonia studies and one 18F-FDG study.

1.3.3

Imaging macrophages

Many PET ligands have been developed to detect upregulation of the mitochondrial
translocator protein (TSPO) in activated microglia, the tissue resident macrophages of the
brain106. Similar to FDG, TSPO is taken up more by pro-inflammatory than antiinflammatory cells107. There is the added limitation that a polymorphism affects TSPO
binding108. Recently it has been shown109 in mice and humans that myocardial
inflammation post-MI could be detected using a TSPO PET ligand. However, in vitro
work101 suggests that this compound is taken up by other inflammatory cells besides M1
macrophages. (It has been reported that the uptake in M1 macrophages is four times
greater than the uptake in M2 macrophages, neutrophils, monocytes, T/NK cells and B
cells.101) The one real advantage over 18F-FDG is that uptake of TSPO PET ligands in the
normal myocardium does not have to be suppressed in order to detect inflammatory cells
remote from the infarcted tissue. However, almost all research has been related to uptake
in microglia and there is a need for more research into the in vivo uptake of TSPO PET
ligands by inflammatory cells.
Other targets for inflammatory tracers include the chemokine receptor CXCR4 which has
been shown to colocalize with CD68 with the additional benefit of not being taken up by
the myocardium. [68Ga] Pentixafor targets this receptor and has been used to image
atherosclerosis and acute myocardial infarction110,111. Somatostatin receptor subtype-2 is
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another promising target for PET imaging and is highly expressed in M1 macrophages.
This can be imaged with radio-labeled DOTATATE (68Ga or 64Cu) and has been applied
in patients with atherosclerosis112,113. Many other targets such as apoptosis114, matrix
metalloproteinases115 or the macrophage mannose receptor (MMR) have been reported
where MMR is upregulated in M2 macrophages116. Some of these options and others are
summarized in figure 1-1.

1.3.4

Injecting labeled inflammatory cells

Although labeling white blood cells has been practiced in nuclear medicine for decades to
detect sites of inflammation, imaging these cells within the myocardium has not been
possible117. This is due to a) partial volume effects and b) the lack of retention of the
tracer within the labeled cells118 . Another problem is that a bolus injection of 18F-FDG
does not allow sufficient delivery of labeled inflammatory cells into the IOT. However,
in animals, 111In labeled white blood cells do accumulate if injected approximately 24
hours prior to sacrifice, as detected by in vitro tissue sample counting119. A recently
developed new PET probe (89Zr-DBN) that labels the (white blood) cell plasma
membrane in a stable manner118 addresses tracer leakage. The attractiveness of a 89Zr
label is its long half-life (3.3d) which would allow the initial high background activity in
the left ventricular cavity to be reduced/cleared. However, effective implementation will
require high spatial resolution anatomic images of the heart (by CT or MRI) that are
reliably registered to the PET image to allow for effective partial volume correction and
confidence in the location of regions of interest corresponding to IOT, INOT and RT
identification. Although quantitation of the 89Zr signal is relatively simple and reliable
compared to quantitation of SPIO iron particles by MRI, there is still the problem of
quantitation of the number of cells. Obtaining the absolute number of cells rather than a
relative amount of inflammation would be ideal for determining the efficacy of antiinflammatory therapy, comparison to histology or future research into the mechanism of
inflammation post-MI. Inflammatory cell proliferation and resultant dilution of the label
interferes with reliable quantitation. As has been shown by Blackwood et al, one likely
advantage over MRI is that, as cells die, 89Zr-labeled debris will likely not be engulfed by
other cells120; whereas, the SPIO particles released by labeled cells as they die have been
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reported trapped in other cells and in the interstitium of the myocardium121,122. Reporter
genes have also been developed for PET. Cells that are transfected and transplanted
directly into the myocardium can be visualized after injection of the needed radiolabeled
substrate123,124. To date, tracking intravenously-injected PET reporter gene-expressing
cells within IOT, INOT and RT has not been accomplished and there remains the general
prohibition of injecting genetically modified cells into humans. Nevertheless, it might be
worth investigating if 89Zr-labeled cells could be developed that would allow
visualization of inflammatory cells in the IOT, INOT and RT regions, if hybrid PET/MRI
were used to identify the anatomical location of the 89Zr activity. Fig 1-1 summarizes the
currently available PET probes and MRI agents discussed.
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Figure 1-1: Availability of PET tracers and MRI approaches for a convergent
hybrid PET/MRI approach to the study of cardiac inflammation post MI.
This figure is an attempt to integrate the PET tracers and MRI approaches available for
the study of inflammation post MI under the categories of myocyte glucose metabolism,
detection of inflammatory cells, measurement of blood flow, examination of changes in
the extracellular matrix (not discussed in the review) and cell death (apoptosis section).
The intent is to suggest a synthesis of the available independent toolbox for PET and MRI
into hybrid PET/MRI.
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1.4

Hybrid PET/MR technology

In Fig 1-2 the sensitivity, spatial resolution, and approximate maximum sample diameter
of PET and MRI are compared and contrasted with other major imaging modalities
(SPECT, CT and optical) for large animal and human imaging. It should be emphasized
that hybrid PET/MRI is a convergence of PET and MRI and unlike PET/CT, which is a
sequential acquisition technology, hybrid PET/MRI allows simultaneous acquisition over
the same anatomical site. As such, although both PET and MRI are mature technologies
when used independently, their combination with hybrid PET/MRI adds a distinct
additional nuance that may take many years to explore and determine the value of hybrid
PET/MRI over sequential PET and MRI.
The engineering feat of integrating a PET ring into the bore of an MRI required a major
redesign of whole-body PET technology125. The equipment challenges that remain
include a) optimization of the RF/MRI receive coils to reduce the attenuation of the PET
signal while maintaining similar performance to dedicated MRI only coils and b) MRbased PET attenuation correction (MRAC) that compares well with CT-based PET
attenuation correction (CTAC). However, it has been shown that artifacts and
misalignment can impact quantitative accuracy of PET imaging by up to 6%72,126. One of
the contributing factors is that the MRAC is often done during breath hold while PET
data is acquired continuously. Lassen, et al, suggest that this can be corrected by taking
µmaps at several respiratory phases or at the end of the exam127. It should also be noted
that contrast administration could lead to misclassification of tissue128. A recent
publication demonstrated high MR performance and low PET signal attenuation with a
32-channel RF array designed prospectively for cardiac PET/MRI129. Furthermore, MRderived attenuation correction of the heart using manufacturer-provided software shows
excellent correlation with corrections using CT125,130,131.
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Figure 1-2: Comparison of the capability of different large animal and human
molecular imaging modalities.
This figure uses a log-log scale of sensitivity on the vertical axis and spatial resolution on
the horizontal axis to demonstrate the capabilities of several imaging modalities. The
limit on spatial resolution is shown as the left edge of each shape, while the approximate
maximum sample size, which is dependent on both instrument design and signal
attenuation, is shown as the right edge. The height of each shape shows the range of
sensitivity estimates. This figure was first published by Goldhawk et al, using data from
several sources and is used with permission. 132–139

1.4.1

Hybrid PET/MR in cardiology

The major limitation in standalone PET (i.e. sequential PET/CT) has been the collection
of data while the heart moves through the combined cardiac and respiratory cycles. This
is in contrast to cardiac MRI, wherein ECG synchronization of the cardiac cycle can be
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combined with breath hold or respiratory gating140. However, respiratory gating of PET
results in loss of 50% of the data and dividing the cardiac cycle into eight phases results
in a total loss of 15/16th of the collected data for each component phase. Methods have
been developed to register cardiac MR images taken at different times in the respiratory
cycle141,142 but to date they have not been effectively used to reduce/eliminate the effect
of motion on the PET data without sacrificing some MRI capabilities143–146. It is possible
that the respiratory and cardiac motion of the heart could be tracked by MRI (e.g. with
3D navigator echoes and motion sensitive MRI acquisitions) and PET lines of response
shifted to a fixed cardiac location (e.g. end diastole at functional residual capacity)147.
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Figure 1-3: Longitudinal comparison of inflammation post-MI with PET/MR in a
canine model.
This figure shows the progression of a myocardial infarction from day 0 (top) to day 21
(bottom). On the left are a multiplanar reconstruction of 3D T1-weighted images showing
a 4-chamber view of the heart, acquired 20 minutes after a bolus injection of Gd-DTPA,
in the middle is an 18F-FDG image and on the right is a combined PET/MR image.
Myocardial glucose uptake is suppressed by lipid infusion and heparin injection. These
images show that the areas of inflammation decrease over time.
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Accurate registration to MRI is needed to effectively implement partial volume
correction of cardiac PET. Although conceptually simultaneous PET/MRI over the heart
has the needed information this has yet to be achieved. Fig 1-3 shows the importance of
PET registration to MR to relate the extent of inflammation to the post-MI tissue types
defined by contrast-enhanced MRI. Also, with good suppression of normal 18F-FDG
myocyte uptake, it is only by MRI registration that the extent of 18F-FDG uptake
associated with the different post-MI tissue types can be identified. The appeal of
“perfect” registration is shown in Fig 1-4 where the FDG-PET and post contrast MRI
images are perfectly registered as the data was taken after euthanasia119. Notice the
potential for sub transmural PET signal localization.

Figure 1-4: Post-mortem images of the left ventricle in a canine model. Hybrid
PET/MRI after constant simultaneous infusion of FDG and Gd-DTPA in a large
animal model of inflammation Post MI.
Registration is “Perfect” as the PET/MRI were acquired post-euthanasia. Arrows
indicate center of infarct (blue) and edges of infarct (orange). Notice that inflammation
by PET extends beyond the infarct into the “remote” left ventricular myocardium but is
not transmural in this “remote” region. Uptake of FDG in the “remote” myocardial
tissue PET images could be further improved by MRI guided partial volume correction.
Suppression of myocardial glucose uptake was achieved through lipid infusion, heparin
injection and fasting.
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1.4.2

Future opportunities with hybrid cardiac PET/MRI

Without marked improved in registration between PET and MRI than what is possible
today, the use of PET radiopharmaceuticals was dependent on low (but not zero) nonspecific binding for anatomical localization of signal. However, with automatic
registration of the MRI image to the PET distribution, PET probes without non-specific
binding can now be developed and used. For example, this enables the tracking of PET
labelled cells. As outlined in the section “Injecting Labeled Inflammatory Cells”, the
tracking of 89Zr labeled cells would be possible if hybrid PET/MRI reliably registered the
PET and MRI images whereas this may not be reliably done with PET/CT or sequential
PET/MR due to the lack of anatomical information from the 89Zr cells and the lack of soft
tissue contrast of CT. 89Zr with its 3.3 day half-life is attractive for longitudinal imaging
since it can be tracked within the body for as long as 3 weeks148.

1.4.3

Constant Infusion Protocol

A constant infusion approach to tracer delivery has been hypothesized to lead to an
equilibrium concentration of the tracer and has been used for dynamic brain glucose
metabolism measurements149,150. This has also been applied in the heart to measure
cardiac function and glucose metabolism during hypoxia151. The constant infusion
provides the equilibrium needed to see a change in glucose metabolism when hypoxia is
applied. The time at which equilibrium is reached has not been quantified. Furthermore, a
constant infusion may allow tracers to enter low-flow areas such as the IOT43. In
combination with the previously mentioned PET/MRI techniques, a combined constant
infusion of MRI contrast agents and PET tracers would allow for penetration of low flow
regions such as the microvascular obstruction.

1.4.4

Hybrid PET/MRI protocols

An opportunity and challenge for hybrid PET/MRI is to optimize the combined PET and
MRI protocols. One of the issues post-MI is delivery to an area of IOT. A bolus injection
of gadolinium chelate does not penetrate IOT and hence allows its discrimination from
the INOT. Although this lack of penetration of the MR contrast agent allows the
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discrimination of the three post-MI tissue types, the lack of penetration of 18F-FDG
blocks information regarding the presence or absence of inflammatory cells in the IOT. A
bolus injection of 18F-FDG does not penetrate this zone sufficiently to give inflammatory
cells the opportunity to sequester the tracer119. A novel and now possible approach would
be to maintain a high blood concentration of tracer for a sufficiently long period of time
to allow increased delivery of the tracer, even to the regions of severely compromised
flow. This could be accomplished by a constant infusion of 18F-FDG and a Gd-chelate. If
the Gd-chelate were able to penetrate the IOT during a 40 min infusion, then it is likely
that 18F-FDG would also be delivered sufficiently to somewhat penetrate IOT and INOT.
A slow infusion would allow accurate 3D T1 maps to be collected as tissue
concentrations would not change appreciably during the acquisition and this would match
the 3D data collection of 18F-FDG-PET. Normally 3D T1 maps cannot be accurately
collected after a bolus injection of Gd-chelate. This would provide unprecedented 3D
data matched in time and space between 18F-FDG-PET and Gd-chelate/MRI. As the
concentration of Gd-chelate would not change appreciably during the 3D T1 map data
collection, subtle changes in the extra-cellular volume could be detected in the remote
myocardium151–153.
One of the major differences between PET and MRI is the flexibility in binning the data
after the acquisition. PET data can be collected in list-mode, where the location and time
of individual PET events is recorded in a large raw data file. If physiological timing
markers are also recorded, it is possible to reconstruct PET images at any point within the
respiratory and cardiac phases. Hence, allowing the elimination of data corrupted by
motion of either physiological origin and/or associated with patient bulk movement. MRI
data is typically collected in a rigid format corresponding to a patterned projection in kspace and MRI images are difficult to accurately reconstruct from an incomplete set of kspace data. Recently this constraint of MRI has been addressed using a novel approach to
randomize k-space data collection that would then allow matching in time of MRI with
“random” PET list-mode image creation154–157. This will harmonize the way PET and
MRI data is collected and used; which is important to fully realize the benefits of
simultaneous acquisition such as improved PET to MRI registration.

22

Figure 1-5: Conventional vs convergent approaches to cardiac hybrid PET/MRI
protocols.
To date, most clinical applications of hybrid PET/MRI in cardiology have adopted
protocols that were developed for sequential PET/MRI, which results in good PET and
MRI images that are analyzed separately. However, good registration of PET and MRI is
not always achieved. With an approach which treats hybrid PET/MRI as a new imaging
modality, achieved through the convergence of the two modalities, cardiac PET/MR
images could be achieved which are not possible with sequential acquisitions. An
example of this potential is shown in Figure 1-4.
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1.4.5

Hybrid PET/MRI as a convergent technology

The convergence of PET and MRI will provide medical imaging with a new imaging
modality. To achieve convergence there is a need for near perfect registration between
PET and MRI as well as other factors outlined in Fig 1-5. A major limitation of PET is
the one common signal (511 keV annihilation radiation) for all PET radioisotopes. This
limits PET to a single radiopharmaceutical during any one data collection whereas in
MRI there is the capacity to collect a variety of image contrasts based on different pulse
sequences and interactions of protons with static and varying magnetic fields. For
example, a post-MI study that requires both blood flow (e.g. 13N ammonia) and
inflammation (e.g. 18F-FDG) by PET is difficult to achieve in a single imaging session.
One possibility is to perform myocardial blood flow measurements using contrastenhanced MRI158 or BOLD MRI159 which could reduce acquisition time and dose during
cardiac examinations, as shown in Fig 1-6. This would be especially useful in diseases
such as cardiac sarcoidosis where it would be advantageous to study blood flow and
inflammation102,160. Reducing the acquisition time and dose would allow investigators to
try new studies which would presently not be possible due to the length of the scan and
the patient’s ability to withstand it. One potential with hybrid PET/MRI is the use of the
Tofts model161 to quantify Ktrans, a transfer constant related to tissue perfusion, during a
constant infusion and how this relates to PET tracer dynamics162. The replacement of
FDG-PET with glucoCEST is intriguing but issues with sensitivity of CEST and the fact
that different glucose pools are being detected requires significant development163. CEST
measurements sensitive to creatine kinase, hyaluronan synthesis, or pH may hold more
promise in combination with complementary PET imaging.
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Figure 1-6: Imaging myocardial perfusion reserve and inflammation with a
convergent PET/MRI protocol.
Using the current state of practice, imaging myocardial perfusion and inflammation
sequentially would take approximately 140 minutes, unacceptably prolonging the exam.
Using convergent technology, this could be reduced to 60 minutes with near perfect
registration, using a rapid dual-injection for 13N-ammonia for measuring rest and stress
blood flow, as suggested by Rust et al.104 However, when injecting the tracer beforehand
or using alternate tracer delivery, and using BOLD MRI instead of PET164, it could be
reduced even further, to 30 minutes or less.

1.4.6

Artificial intelligence with hybrid PET/MRI

In an extensive state-of-the-art review on artificial intelligence in cardiovascular disease,
cardiac PET and cardiac MRI are treated separately165. The major limitation for the
application of AI to hybrid PET/MRI for the detection of disease is the absence of a large
cohort of “ground truth” data needed for the training sets. Some of the outcomes of AI as
applied separately to PET and MRI suggest some applications to improve the quality of
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information. For example, the 2016 Kuggle Data Science Bowl competition provides
more than 1,000 cardiac cine MR data sets and the AI developed has shown that left
ventricular end-systolic and end-diastolic volumes can be determined166. If this approach
could be used to identify these volumes and also the epicardial and the endocardial
borders at the same respiratory and cardiac phases as in the PET data simultaneously
collected, then this could allow identification of the location of these cardiac structures in
the PET images, even if in the PET images these structures were not visible. Not only
would this automation reduce image analysis it would also allow the identification of the
same structures in the PET data. Unfortunately, to the best of our knowledge, the needed
PET ground truth data are not available, even for the development of machine learning
approaches to assist in the determination of diagnostic values. It would be of considerable
value if there were cardiac PET/CT and MRI data of the same patients even if acquired
separately. For example, the Alzheimer’s Disease Neuroimaging Initiative archived data
sets include brain PET and MRI images of the same patient and would allow sufficient
training sets to develop AI for joint PET/MRI reconstructions, partial volume correction,
MR-derived attenuation correction and dose reduction, to name a few. These findings, in
turn, could be tested with true hybrid PET/MRI data sets. Unfortunately, there are no
such large data sets for separate cardiac PET and cardiac MRI on the same patients. It
seems inevitable that the data would have to be collected on hybrid PET/MRI systems to
test joint reconstruction, kinetic modeling and partial volume correction. As we have
suggested already, optimizing AI outcomes of combined simultaneously acquired PET
and MRI data will require data collection protocols which are very different than what is
collected for standalone MRI. Both supervised and unsupervised approaches should be
explored with respect to combined connected model analysis. The number of fitted
parameters should be small and restricted in supervised approaches whereas in the
unsupervised approach many more parameters can be investigated165. Another example
would be the use of MRI guided PET reconstruction to reduce radiation dose by
constraining the PET reconstruction to reduce the effect of noise.
A common AI approach is to try to simulate another, gold-standard modality, e.g.
generating a pseudo CT with MRI for MRAC or predicting Gd-enhanced images with
non-contrast MRI. Can we use this approach with matched MRI and PET to predict
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regions of inflammation? That is, can we get enough information from multiparametric
MRI (Gd-enhanced, blood flow, T2-weighted, T2*-weighted, and CEST) to predict
where inflammation should be and validated with FDG-PET or TSPO-PET?

1.5

Preclinical benchmarking using animal models

Significant advances in cardiac imaging have often required the use of animal models
allowing for the establishment of ground truth directly from tissue. Both small animal and
large animal models have been effective. For example, most recently, Thackeray et al109
used an infarct mouse model to test the use of a TSPO-PET ligand before moving to
human studies. In contrast, large animal models, although more expensive, are needed
since the physiology of the models better reflects the human condition and/or the imaging
cannot be easily scaled up to humans if a small animal model were used. For example,
most recently, Yang et al developed cardiac BOLD applications in the canine as a rodent
model would not have been of value in developing cardiac BOLD for human
application65. Translation of therapeutic interventions from rodents to humans has, in
general, had a high failure rate167. For the development of imaging biomarkers, this
problem is exacerbated by the non-linear scaling from rodent to human imaging
modalities92,137–139. In contrast, large animal models have a reasonable translation
record168,169 and little or no issues with scaling of PET and MRI since studies use human
imaging equipment. Regarding coronary artery disease and inflammation, a) infarcted
myocardium results in an increase in the distribution volume of Gd-DTPA, characteristic
of permanently damaged myocardium, in dogs and humans42,47,170–172 but the increase in
the distribution volume in rats also occurs in reversibly damaged tissue173; b) the time
course of neutrophil and macrophage activity following AMI is similar in dogs and
humans, but different in rodents15,174–176; c) inflammatory cell response post AMI has the
same cell markers in humans and dogs6,177; and d) the course of hemorrhage and iron
precipitation following AMI is similar between humans and dogs. There has been some
debate regarding the use of porcine rather than canine models for the study of the
evolution of acute infarction. The presence of collateral vessels in the canine myocardium
is more relevant to AMI in older humans (>50 yrs of age) while the lack of collaterals in
pigs provides a better model for sudden death. Since progressive heart disease following
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AMI is predominantly seen in older individuals, the canine model is superior for imaging
inflammation post-MI178,179.

1.6

Summary

Standalone myocardial post-MI MRI can provide discrimination of the three tissue types:
IOT, INOT and RT. It also can provide functional information, extent of edema and
extent of hemorrhage. It can partially track/detect inflammatory cells if they can be
labelled with iron particles or 19F. Standalone PET (i.e. PET/CT) can quantify
inflammation with 18F-FDG or TSPO-targeted tracers, but not specifically with respect to
pro-inflammatory vs. the anti-inflammatory signal and, in the case of 18F-FDG, requires
myocardial suppression which is not always successful. A hybrid PET/MR approach
including a contrast agent sensitive to anti-inflammatory signal may be able to separate
the pro- and anti-inflammatory signals. Hybrid PET/MRI, even with its current state of
non-optimal cardiac registration, provides a complementary story that will allow the
relationship between scar formation and inflammation to be discovered as is being done
in other cardiac conditions such as sarcoidosis102,180.
To date, the primary use of hybrid PET/MRI is to perform combined PET and MRI
procedures in a single procedure primarily as a tool of convenience rather than as a
means of greater understanding of pathophysiological mechanisms. To achieve the latter,
there are four important areas of development: that are required: a) far better registration
than what is available today that does not significantly sacrifice the acquisition of PET
data; b) synchronized, simultaneous acquisition of PET and MRI where MRI must have
the same flexibility as list-mode PET c) integration of quantitative and novel MRI
techniques such as cardiac BOLD; and d) an approach that combines the large number of
PET probes and determinants of MRI contrast in novel synergistic ways (see Fig 1-1).
This will not only be impactful with currently available PET probes but would make it
possible to develop new PET probes or combined PET/MRI strategies that could
quantitate and differentiate between the different inflammatory cell phenotypes.
Discrimination between the pro- and anti-inflammatory processes in the three tissue types
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post-MI will be critical for the development of inflammatory therapies and for
implementation in the individual patient.

1.7

Research Objectives

In this thesis, primarily the constant infusion approach to tracer and contrast agent
delivery will be examined. Previously, a constant infusion of PET tracers has been used
to examine cardiac metabolism during hypoxia151 in a porcine model and a constant
infusion of Gd-DTPA has been used to examine perfusion in a canine model with MRI
only43. However, they have not been combined in one model or post-MI while imaging
with PET/MRI. It has also not been determined whether the constant infusion approach
leads to the same results of extracellular volume and glucose metabolism as a clinical
bolus injection and whether it is safe to combine FDG and Gd-DTPA in the same syringe.
This leads to several research objectives:
1. Since the safety of combining Gd-DTPA and FDG in one syringe has not been
shown, the first goal in this thesis was to show that combining these is safe since
they will be combined to complete the following objectives.
2. Before applying the constant infusion method in a model of myocardial infarction,
it had to be shown at baseline that the glucose metabolism and extracellular
volume were not significantly different. Thus, the second objective was to
determine whether the results from a bolus injection and a constant infusion are
the same.
3. The third objective of this thesis was to measure glucose metabolism and
extracellular volume post-myocardial infarction in all regions of the heart
including RT, INOT and IOT.
4. The fourth objective was to determine whether a long constant infusion of 150
minutes can penetrate the IOT with both FDG and Gd-DTPA.
5. The fifth and final objective was to determine whether the current technique to
suppress myocardial glucose uptake of fasting, heparin injection and lipid infusion
is effective.
Overall, this will validate the constant infusion approach with hybrid PET/MRI and it
may allow measurements of inflammation in the RT, INOT and IOT.
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1.8
1.8.1

Thesis Outline
Simultaneous measurements of myocardial glucose
metabolism and extracellular volumes with hybrid PET/MRI
using concurrent injections of Gd-DTPA and [18F]FDG

In Chapter two, Simultaneous measurements of myocardial glucose metabolism and
extracellular volumes with hybrid PET/MRI using concurrent injections of Gd-DTPA and
[18F]FDG, the first two objectives were addressed: the safety of combining gadoliniumbased contrast agent and FDG in one syringe and comparing the results from a bolus
injection and a constant infusion at baseline. FDG and Gd-DTPA were combined in a
single syringe for 90 minutes and analysed for changes in pH and radiochemical purity
and identity with radiometric thin layer chromatography. In addition to that, 6 healthy
canines were imaged with PET/MRI with 3 different injection protocols of combined GdDTPA and FDG: 60-minute constant infusion, bolus injection and bolus injection
followed by a 30-minute constant infusion. All of these were done without suppression
and then repeated with suppression by heparin injection and lipid infusion. Note that
animals were fasted in either case as a requirement for anesthesia181.

1.8.2

Tracking the progress of inflammation with PET/MRI in a
canine model of myocardial infarction

In chapter three, Tracking the progress of inflammation with PET/MRI in a canine model
of myocardial infarction, the third objective, measuring glucose metabolism and
extracellular volume over time post-MI, was addressed. Eight animals were imaged at
baseline and on days 3, 7, 14, 21 and 43 with hybrid PET/MRI during a constant infusion
of Gd-DTPA and FDG. Glucose metabolism and extracellular volume were measured in
RT, INOT and IOT. The values of both are compared among days so that a timeline of
inflammation can be established in all tissues182.

1.8.3

Investigating the effects of myocardial glucose suppression
on the incorporation of FDG into pro-inflammatory cells in a
canine model of myocardial infarction

In chapter four, Investigating the effects of myocardial glucose suppression on the
incorporation of FDG into pro-inflammatory cells in a canine model of myocardial
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infarction, the fourth and fifth objectives were addressed. As such, the degree of
penetration of tracer and contrast agent into the IOT was measured and the effect of
myocardial glucose suppression on inflammatory cells was investigated. To determine
the impact of myocyte glucose suppression, the constant infusion was increased from 60
min to 150 minutes in 6 animals studied at baseline and at day 5 post-MI. This allowed
measurements of glucose metabolism without suppression to be measured in the infarcted
tissue for the first 40 minutes of the constant infusion. This result was then compared to
the glucose uptake in this infarcted tissue during active suppression for the period of 50
to 90 minutes and then again after the suppression for the period from 100 to 150
minutes.

1.9
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Chapter 2

2

Simultaneous measurements of myocardial glucose
metabolism and extracellular volumes with hybrid
PET/MRI using concurrent injections of Gd-DTPA and
[18F]FDG
2.1

Introduction

Pathological alterations in myocardial tissue composition can be assessed using
cardiovascular magnetic resonance imaging1. Absolute T1 relaxation times throughout
the myocardium can be quantified using T1 mapping before and after administration of a
gadolinium-based contrast agent (GBCA)2. Pre- and post-contrast T1 maps can be
combined to give a direct measure of the extracellular volume (ECV)2,3. Myocardial
fibrosis, a crucial component of the pathologic remodeling leading to heart failure, is
characterized by myocardial extracellular matrix expansion and accumulation of
interstitial collagen4. GBCA track extracellular collagen, which is the principal
constituent of the expanded extracellular matrix and ECV mapping has shown promising
results with respect to characterizing the extent of infiltrative and fibrotic cardiac
diseases, such as sarcoidosis3–5.

In order to quantify ECV accurately in the heart, single-slice breath hold T1 maps must
be acquired spanning the entire heart3,6,7. For full heart coverage and artifact elimination,
this requires acquisition during which the concentration of GBCA in the blood and tissue
should not be changing significantly3,6,7. A bolus injection followed by a constant
infusion of GBCA, given the correct timing and dose distribution between the bolus and
constant infusion, achieves relatively rapid, constant blood concentrations which can be
sustained for up to one hour3,6–8. Clinically, however, ECV is normally measured after a
bolus injection of a GBCA (without an infusion)9, but the results may be affected by the
constantly changing blood and perhaps resultant tissue contrast levels. However, there are
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no studies that have investigated the effects on tracer concentrations and image data using
only a prolonged constant infusion without a preceding bolus. An accurate and
reproducible measurement of the distribution volume (VD) of GBCA, could lead to a
more in-depth understanding of the pathology of both healthy and injured myocardial
tissue.
PET can provide additional complementary information to MRI particularly when PET
and MRI are combined as a hybrid platform10,11. [18F]FDG PET/MRI is increasingly used
for the detection of cellularly-mediated cardiac inflammation, particularly in sarcoidosis
and, more recently, in myocardial infarction11,12. Using hybrid PET/MR with concurrent
[18F]FDG and GBCA injections would reduce overall imaging time and can facilitate
optimal registration of the PET and MRI images10,11. However, assessment of myocardial
inflammation also requires suppression of myocyte uptake of [18F]FDG to be able to
differentiate between physiological and pathological uptake of FDG by inflammatory
macrophages11. Clinically, suppression of glucose is accomplished using intravenous
heparin and a high fat diet11. Heparin is a glycosaminoglycan and therefore exerts a
strong osmotic pressure on cells13. Joerges et al. has shown that extracellular heparin
significantly increased the cell volume of fibroblasts in vitro13, potentially altering the
intra/extracellular volume relationship. However, the effects of heparin on ECV in vivo
remain unclear.
This study was performed to determine if the issues identified above associated with
differing infusion protocols and concurrent injections of GBCA and [18F]FDG while
performing myocardial glucose suppression affect the determination of myocardial ECVs
and glucose uptake. These were investigated in the setting of three different injection
protocols: bolus, constant infusion only and a bolus followed by constant infusion.
Further, to determine the chemical stability of the compounds when combining GdDTPA and FDG, we used radiochromatography on a mixture of FDG and GBCA, once
with a linear gadolinium chelator (Gd-DTPA, Magnevist, Bayer) and once with a cyclic
chelator (gadobutrol, Gadovist, Bayer).
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2.2
2.2.1

Materials and Methods
Animal Preparation

The care and treatment of the animals was in accordance with the University of Western
Ontario Council on Animal Care (Animal Use Subcommittee) guidelines. Five healthy
female canine subjects were imaged to compare the three different protocols for injecting
Gd-DTPA: the standard bolus injection approach, delivery by a constant infusion over 60
minutes without a bolus, or use of a bolus followed by a 30 minute constant infusion. The
adult, female, bred-for-research hounds weighed 18-23 kg. Anesthesia for all procedures
was induced using propofol and maintained with 1.5% - 2% isoflurane (Forane, Baxter).
When required by the imaging protocol, the suppression of myocardial glucose uptake
was induced using a continuous infusion of 20% lipid (Intralipid; Baxter Healthcare
Corporation) at a rate of 0.25mL/min/kg over a 50-minute period as well as 2000 units of
intravenous heparin injected 20 minutes prior to FDG/Gd-DTPA injection11. This we
have shown is the most effective approach in canines.12 The requirement of the intralipid
infusion may be related to the difference between the diet of dogs compared to humans.
Note also that the effective use of heparin in humans is listed by weight14 whereas in dogs
we simply used a fixed dose as the weight of all animals was similar i.e. 18-23 kg.

2.2.2

PET/MRI Protocol

All canine subjects were imaged with a Siemens Biograph mMR 3T clinical scanner. The
animals were placed in a right lateral recumbent position and 3 electrodes were
positioned on the chest. Gd-DTPA and [18F]FDG were injected through an intravenous
line. The same five canine subjects were scanned on two different occasions for each of
the three different injection protocols shown below (also on different days), once with the
extensive protocol for suppression of glucose uptake by the myocardium and then again
without this suppression protocol i.e. six different scanning sessions per canine (See
figure 2-1 for sample images from 1 animal). Due to two unsuccessful experiments in the
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bolus only work (figure 2-4b), two animals had only one bolus scan done, one of the
suppressed, the other unsuppressed.

Figure 2-1: Suppression differences based on injection type with FDG imaging.
This figure shows the suppressed vs unsuppressed FDG images in a single animal (D1)
with the same image intensity leveling. In this animal, clearly suppression was effective
in bolus and constant infusion. As all animals are fasted prior to the scan, as necessitated
by the anesthesia, it is likely that this alone may be enough to suppress myocardial
glucose uptake in some cases as shown in this animal for the bolus + constant infusion
case.
As shown in figure 2-2, each canine was injected a total of 0.24mmol/kg of Gd-DTPA
(Magnevist, Bayer Inc.) and 10.2 MBq/kg of FDG (produced in-house at the SJHC
Cyclotron facility) for each of the three injection protocols. For the constant infusion only
protocol, a 60-minute constant infusion (0.004mmol/kg/min of Gd-DTPA and 0.17
MBq/min/kg FDG) was administered followed by 30 minutes of washout. During the
bolus followed by a constant infusion, a bolus of 0.12mmol/kg Gd-DTPA and 5.1
MBq/kg FDG followed by a 30-minute constant infusion (0.004 mmol/kg/min Gd-DTPA
and 0.17 MBq/kg) was administered followed by an additional 30 minutes of washout.
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Cardiac T1 maps (4-chamber view of the heart) were acquired with a modified LookLocker inversion recovery (MOLLI) sequence (ECG-gated, 35° flip angle, 256 x 218
matrix size, 300 mm x 255.5 mm field-of-view, 6 mm slice thickness, 400ms repetition
time, 1.12ms echo time) during breath hold at pre-contrast and then every 3 min after the
concurrent injections: for a total of 60 min after the bolus and bolus plus constant
infusion protocols and for 90 minutes following 60 min constant infusion protocol. Note
that this included 30 min of washout after the end of the constant infusions.
The PET data was reconstructed in 3-minute frames using a 3D Ordered Subset
Expectation Maximization (OSEM) reconstruction (3 iterations, 21 subsets, 172 x 172 x
127 matrix size, zoom of 2 and 4 mm Gaussian filter). Attenuation correction was
achieved using a two-point Dixon MRI sequence and segmented into water, fat, lung and
air with constant attenuation coefficients for each tissue. The PET voxel size was 2.09 x
2.09 x 2.03 mm. All PET data was acquired in list-mode for 60 minutes in the bolus-only
protocol and bolus followed by CI and 90 minutes for the constant infusion only protocol.

Figure 2-2: Injection protocol with three different injection strategies.
Three different injection strategies of [18F]FDG /Gd-DTPA were used: a) a bolus
injection only, b) a bolus followed by a 30-minute constant infusion (Bl + Cl), and c) a
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60-minute constant infusion. In the imaging procedure in which glucose metabolism was
suppressed a continuous infusion of intralipid and an intravenous heparin injection were
administered 20 minutes prior to [18F]FDG /Gd-DTPA injection and MOLLI acquisition.

2.2.3

Image Analysis

Image analysis was performed using 3D Slicer (Open Source, BSD License) and
MATLAB (Mathworks, R2019a). As shown in figure 2-3, manually drawn regions of
interest (ROIs) in the 4-chamber view were used to identify the healthy myocardium and
the left ventricular blood pool. Myocardial and blood T1 values pre- and post- Gd-DTPA
administration were measured. Once the ROIs were defined, they were used as a template
and copied to the rest of the images in the series. Manual adjustment of some images in
the series was applied to offset changes in heart position. Edges were also avoided when
drawing ROIs to minimize partial volume averaging from voxels at the myocardial-blood
pool border. ECV was calculated using the following formula where hematocrit was
assumed to be 0.4515. For the comparison of ECV using different injection types with and
without glucose suppression, steady-state equilibrium was assumed to be reached when
the difference in the calculated ECV between acquisitions was less than 5%, as done by
White et al16 with the following equation:
𝐸𝐶𝑉 = (1 − ℎ𝑒𝑚𝑎𝑡𝑜𝑐𝑟𝑖𝑡)
1
1
𝑝𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑇1 𝑚𝑦𝑜 − 𝑛𝑎𝑡𝑖𝑣𝑒 𝑇1 𝑚𝑦𝑜
×
.
1
1
−
𝑝𝑜𝑠𝑡 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑇1 𝑏𝑙𝑜𝑜𝑑 𝑛𝑎𝑡𝑖𝑣𝑒 𝑇1 𝑏𝑙𝑜𝑜𝑑

Eq 1
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Figure 2-3: Region of interest selection at baseline.
Extracellular volume (ECV) measurements were calculated for three separate regions:
two in the healthy myocardium (white ROI’s) and one ROI in the blood pool (purple
ROI). The ECV was then averaged from the ROI’s from the healthy myocardium, using
cardiac T1 maps acquired during breath hold at pre-contrast and then every 3 minutes
following initial injection(s) of GBCA.

2.2.4

Glucose Metabolism

Using an in-house MATLAB script, the FDG concentration curves of all ROIs were fit to
the Patlak model of graphical analysis17 using the following equation:
𝑡

[𝐹𝐷𝐺(𝑡)]𝑖 = 𝐾𝑖 ∫ [𝐹𝐷𝐺(𝜏)]𝑝 𝑑𝜏 + (𝑣𝑒𝑃 + 𝑣𝑝𝑃 )[𝐹𝐷𝐺(𝑡)]𝑝 ,

Eq 2

0

where [𝐹𝐷𝐺(𝑡)]𝑖 is the concentration of [18F]FDG in tissue i, 𝐾𝑖 , the influx constant
which is proportional to the rate of glucose metabolism in tissue i. [𝐹𝐷𝐺(𝑡)]𝑝 is the
arterial plasma concentration input function which was the blood pool ROI, taken from
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𝑝

within the left ventricular cavity. 𝑣𝑒 is the equilibrium space of the extravascular
exchangeable region and 𝑣𝑝𝑃 the plasma space.
[𝐹𝐷𝐺(𝑡)]𝑖

The influx constant, 𝐾𝑖 is determined from the slope of [𝐹𝐷𝐺(𝑡)] 𝑣𝑠

𝑡

∫0 [𝐹𝐷𝐺(𝜏)]𝑝 𝑑𝜏

𝑝

[𝐹𝐷𝐺(𝑡)]𝑝

. This

slope will be 𝐾𝑖 once it is constant, at t = t*, which was operationally defined to be 12
minutes after the start of the constant infusion at which point equilibrium was achieved.
[𝐹𝐷𝐺(𝑡)]𝑝 was determined from the blood concentration [𝐹𝐷𝐺(𝑡)]𝑏 corrected by the
glucose plasma:whole blood ratio (P) of 1.37518 and the haematocrit (Hct) i.e. [FDG(t)]p
= [FDG(t)]b (P/(1-Hct)). The tissue concentration was corrected for the partial volume
effect in PET using a recovery coefficient (RC) of 0.7 determined for a 10 mm diameter
cylinder on our PET/MRI imaging system (approximately equivalent to the thickness of
the left ventricular wall)19,20 i.e.
[𝐹𝐷𝐺(𝑡)]𝑖 =

[𝐹𝐷𝐺(𝑡)]𝑡 1 − 𝑅𝐶
[𝐹𝐷𝐺(𝑡)]𝑏 .
−
𝑅𝐶
𝑅𝐶

Eq 3

Using this method, 𝐾𝑖 was extracted for all ROIs in all studies.

2.2.5

FDG stability under concurrent injection with GBCAs

To a 10 mL vial of Magnevist (Gd-DTPA) or Gadovist (gadobutrol) was added 300 – 500
MBq of [18F]FDG. The vial was stored upright at ambient temperature (20 – 22 oC).
Samples were extracted at 15, 30, 60, and 90 min following initial mixing. These samples
were analyzed for changes to pH (colorimetric paper test) and radiochemical purity and
identity (radiometric thin layer chromatography or radioTLC) compared to [18F]FDG
prior to mixing with GBCA. Both pH and radioTLC test methods were identical to
standard testing methods for release of clinical [18F]FDG. The linear range for the
radioTLC was 82 – 2290 kBq with a limit of detection of 1.6 kBq at the time of testing.
An impurity with 3.3 MBq/mL concentration could reliably be detected. FDG was
visualized on the TLC by coating with 10% H2SO4 in methanol and heating to give a
brown spot.
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2.2.6

Statistical Analysis

Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla,
CA). All data is presented as mean  standard error of the mean (SEM) except for Figure
2-7 where mean +/- SD is used. The effect of different protocols on ECV over time were
compared using a two-way repeated-measures analysis of variance (ANOVA) followed
by Bonferroni multiple comparisons tests. Paired two-tailed t-tests were performed to
compare ECV prior to and following washout for the constant infusion protocol.
Comparison of differences in ECV and Ki associated with glucose suppression and
injection protocol including during washout of Gd-DTPA was assessed with paired and
unpaired two-tailed t tests. A p-value of <0.05 was considered to be statistically
significant. Bonferroni’s method was done to correct for multiple comparisons when
comparing multiple treatments’ means.

Results

2.3
2.3.1

FDG stability under concurrent injection with GBCAs

At all timepoints, no changes were observed in pH or radiochemical purity. As shown in
Table 1, radiochemical identity is confirmed by comparing the retention factors (distance
analyte travels versus solvent front) between authentic FDG standard and [18F]FDG. The
percent difference between the two retention factors was within 6.4 ± 1.7% and 6.5 ±
3.1% when mixed with Magnevist (Gd-DTPA) and Gadovist (gadobutrol), respectively.
This is well within the release specification of 10% and typical of day-to-day variance
during clinical productions.
Table 1: Chemical Stability when combining Gd-DTPA or gadobutrol and FDG
Time after

Retention Factor Mixed with Gd-

Retention Factor Mixed with

mixing

DTPA

Gadobutrol

(minutes)

Original

FDG

[18F]FDG

% Difference

FDG

[18F]FDG

% Difference

0.41

0.43

3.0

0.41

0.43

3.0

62

15

0.33

0.32

4.4

0.44

0.40

9.1

30

0.38

0.35

7.9

0.42

0.42

1.1

60

0.36

0.38

4.9

0.43

0.39

8.2

90

0.36

0.33

8.2

0.41

0.38

7.5

Average

0.37

0.36

6.4

0.42

0.40

6.5

StDev

0.03

0.04

1.7

0.01

0.02

3.1

2.3.2

Evaluation of ECV in Healthy Myocardium with and without
glucose suppression

As shown in Figure 2-4, there was no significant effect of glucose suppression vs. no
glucose suppression on the measured ECV at equilibrium irrespective of which infusion
protocol was used (bolus-only: p=0.22; constant infusion-only: p=0.10; bolus followed
by constant infusion: p=0.09). However, when comparing ECV with glucose suppression
across all animals, irrespective of injection method, ECV is significantly higher with
suppression (0.21 ± 0.02 vs 0.18 ± 0.01, corresponding to a 13% increase; p = 0.002).
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Figure 2-4: The effect of glucose suppression on healthy non-infarcted myocardial
ECV.
Suppression was achieved with a continuous infusion of 20% lipid as well as intravenous
heparin (2000 units). a) The mean ± SEM ECV for all injection types after equilibrium
was reached. No significant differences were found using paired t-tests. The ECV with
and without suppression following a b) bolus injection (note that there are only 4 data
points given for suppression and no suppression as, due to experimental error, one
animal did not have an initial unsuppressed successful experiment and one did not have a
successful suppression study), c) Bl + CI injection and d) CI only for each individual
canine. The ECV values used corresponded to when equilibrium was reached within the
healthy myocardium.
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2.3.3

Comparison of ECV in Healthy Myocardium –
Measurements using Different Injection Types

When comparing the injection protocols, i.e. a bolus, bolus followed by constant infusion,
or a constant infusion, as shown in Figure 2-5, there was no significant difference (p =
0.21) between protocols from minute 9 to minute 60. Minute 9 was chosen to exclude times
when the tracer is still washing in and therefore may not be representative of the actual
ECV. However, over time, the ECV calculated following the bolus injection slowly
increased reaching a plateau at minute 18 (0.21 ± 0.02) with a significant difference (p =
0.02) between minute 3 vs. minute 18. There was no significant difference found for ECV
using the constant infusion protocol at minute 60 when compared to any of the time points
beyond that point, i.e. during the 30-minute post infusion washout period.

Figure 2-5: The time course of changes in the measured ECV of Gd-DTPA in
healthy myocardium in five canine subjects, with glucose suppression, measured
every 3 minutes for up to 90 minutes after start of injection.
Data are presented as mean ± SEM, N=5 for each injection method. All injection
protocols ended at 60 minutes, except for the constant infusion of Gd-DTPA, which
included an additional 30-minute washout period. No significant difference was found
when comparing the different injection methods.
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2.3.4

Glucose metabolism using Patlak parameter estimates

Figure 2-6 shows the influx constant, Ki, a marker of glucose metabolism for healthy
non-infarcted cardiac myocardium with and without glucose suppression using heparin
and a continuous infusion of 20% lipid. There was no significant effect of glucose
suppression on the measured Ki irrespective of which infusion protocol was used (bolusonly: p=0.19; constant infusion-only: p=0.36; bolus followed by constant infusion:
p=0.93).

Figure 2-6: The effect of glucose suppression on healthy non-infarcted cardiac
myocardium Ki, a marker of glucose metabolism.
This figure shows the Ki of each individual canine with and without suppression
following a a) bolus injection, b) Bl + CI injection and c) CI only for each individual
canine. No significant differences were found using paired t-tests. The individual dogs
are identified as D1 to D5 and suggests that the pattern of differences with and without
suppression is not related to individual animals.
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2.3.5

Change in T1 during each contrast delivery method

As shown in figure 2-7, while values in the bolus experiment are increasing over time, in
the bolus followed by CI, values are relatively constant between 10 and 30 minutes and in
a constant infusion only, they are best between 40 and 60 minutes. These durations may
also be increased by increasing the duration of the infusion as they only change when the
infusion is terminated. It is important to point out that these timelines are for healthy
tissue with blood flow of approximately 1 ml/min/g and they may vary in ischemic tissue,
e.g. infarcted tissue, with reduced blood flow.
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Figure 2-7: Changes in T1 values over time in both the myocardium and the blood.
These are mean values +/- SD for all 5 canines in the suppressed glucose myocardium
group.
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2.4

Discussion

The main findings were: (a) The suppression of myocardial uptake of [18F]FDG with
heparin and lipid infusion may alter the determination of myocardial ECV using GBCA,
(b) the infusion protocol used had no effect on the calculated ECV; but with the caveat of
(c) ECV measured using a bolus of Gd-DTPA was underestimated if measured prior to
the first 15 minutes following injection and (d) combining Gd-DTPA and FDG for
concurrent injection for hybrid imaging showed no changes in pH or radiochemical
purity of [18F]FDG.
This work demonstrates the equivalence of the determination of ECV under the different
injection scenarios for the collection of a T1 map over a single slice when the
concentration of GBCA did not vary significantly during the breath hold needed for
acquisition. However, a T1-map of ECV over the entire left ventricular myocardium is
needed if inflammatory disease is non-uniformly distributed as is most often the case e.g.
post myocardial infraction, cardiac sarcoidosis, etc21,22. As a 3D T1 map would require 10
or more 2D slices to be acquired each over a breath hold in a sick patient, this could
easily take 10 or more minutes21,22. During that time, GBCA concentration would be
dropping after a bolus injection, rendering the T1 maps inconsistent between slices.
However, contrast agent concentrations vary more slowly and to a lesser degree during a
constant infusion either following a bolus injection between 10 and 30 minutes, or after
the first 40 min of a constant infusion only protocol (see figure 2-7). Although we did not
assess the effect of prolonged acquisition times (with accompanying ongoing changes in
contrast agent concentrations) on the resulting T1 map, avoiding the variations in blood
concentration associated with the use of only bolus injections of GBCA would minimize
fluctuations in blood tracer concentrations and give us more accurate and precise
measurements of ECV. This would also be expected in remote myocardium following
myocardial infarction, provided myocardial blood flow remains close to 1 ml/min/g as
has been previously shown in this animal model6,8,23. It will be important to validate this
concentration dynamic as a function of injection protocol in myocardium with
compromised blood flow in regions with microvascular obstruction where blood flow is
severely reduced24.
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For the clinical assessment of inflammation by [18F]FDG using simultaneous PET/MRI,
suppression of physiological myocardial glucose uptake is generally achieved by a
method similar to the one we have used in our study, with the intralipid infusion replaced
by a high fat diet25. No significant difference was found between measured ECV with
glucose suppression and non-suppressed myocardium when comparing individual groups.
When comparing suppressed vs non-suppressed irrespective of injection protocol, there
was a significant difference (0.21 ± 0.02 vs 0.18 ± 0.01, corresponding to a 13% increase;
p = 0.002). Further experiments are necessary to investigate whether this effect is from
the lipid infusion, which could decrease the hematocrit. This may be an important
consideration for experiments utilizing a lipid infusion while measuring ECV, although
further experiments are necessary to examine whether the lipid infusion affects the
hematocrit or another part of ECV.We also saw that ECV appears to increase over the
initial 18 minutes following the bolus injection protocol. This suggests that to assess ECV
accurately, one should wait at least 20 minutes and then perform the T1 map
acquisitions26,27. Schelbert et al. also reported a small but statistically significant change
of Ve (extravascular extracellular volume fraction) after bolus injection of GBCA, which
is consistent with our results27. Clinically, an increase in the measured ECV over 18
minutes may be relevant if the MOLLI sequence is not acquired at identical post-contrast
delay times27. This might require careful attention to imaging delay time when using a
bolus or post-scan correction to compensate for the small increase27.
While the safety of FDG and GBCA have both been determined independently, to the
best of our knowledge the compatibility of the two contrast agent mixture has not been
shown. For instance, the linear and cyclic aminopolycarboxylic acid chelators could
potentially conjugate to FDG via glycosylation. De-fluorination was another minor
concern. In this paper, we show an initial assessment at ambient temperature that neither
attachment of chelate to the FDG nor loss of fluoride were observed. Although this data
is consistent with the safety of a combined injection, further investigations on the effect
of physiological temperature during mixing and blood sampling after concurrent injection
would further increase confidence.
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In our study we did not see the expected decrease in Ki, a measure of glucose uptake,
with glucose suppression. When we compare the non-suppressed group to the suppressed
group independent of injection strategy, suppression did not have a significant effect on
glucose metabolism (p=0.27, non-suppressed 0.010 ± 0.008, suppressed 0.0063 ± 0.009).
In all cases the non-suppressed values were below 0.035 ml/min/g. In the suppressed
group, all were below 0.02, with 11 of the 14 below 0.005 ml/min/g. It is clear that
suppression worked well for the non-suppressed values above 0.02 but had minimal and
even contrary results for values already as low as can be achieved with suppression. As
all animals were fasted but the suppressed group was also given heparin and intralipid,
perhaps the requirement to fast canines for 12-16 hours prior to anesthetic was sufficient
to suppress glucose uptake, or the use of only 5 animals may not have provided enough
statistical power to establish the presence of a statistically meaningful effect (figure 2-6a
and c do suggest a downward trend). Our results are promising as hybrid PET/MR
imaging is being used more and it gives the ability to image aspects of inflammation
through both modalities simultaneously. To this we have shown in a canine model that
concurrent FDG and GBCA injections can be safely used, and do not affect the glucose
metabolism and ECV measurements which reduces overall imaging time and ensures
optimal registration of the PET and MRI images.
However, our work has limitations: a) While the sample size of this experiment is
relatively small, this research provides a starting point for future clinical or pre-clinical
experiments. Power analysis has shown that significant differences in ECV for
suppressed vs unsuppressed tissue could be reached in each injection protocol with as
few as 7 animals in CI and bolus followed by CI group whereas a total of 13 animals
would be needed in the bolus only group if the mean and standard deviation were the
same as in the current groups. b) Only partition coefficient, and not ECV, was evaluated
due to lack of hematocrit data, but results can be directly translated to ECV for clinical
relevance as the only difference between partition coefficient and ECV is hematocrit
correction and thus a hematocrit of 0.45 was assumed for this study. c) The use of a linear
gadolinium chelator, Gd-DTPA (Magnevist) in our experiment has been discontinued
(after the start of this experiment) in favour of macrocyclic GBCA’s due to association
with an increased risk of brain retention. However, ECV represents a physiological
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parameter and is derived from the ratio of T1 signal values and is likely not affected by
type of extracellular GBCA used and therefore our results can still be translated for
clinical relevance. d) Hybrid PET/MRI is currently not in widespread clinical use. While
this may change as the modality becomes more accessible and more methods are
developed, not many research centres and hospitals will currently be able to take
advantage of these results.

2.5

Conclusion

Suppression of myocardial uptake of [18F]FDG, through a continuous lipid infusion and
an intravenous heparin injection, has no effect on ECV using GBCA compared to
unsuppressed tissue. Additionally, the infusion protocol used (bolus alone, CI alone,
bolus followed by CI) had no effect on the calculated ECV at equilibrium, however, ECV
measured using a bolus of Gd-DTPA was underestimated if measured prior to the first 15
minutes following injection. Lastly, we have shown that combining Gd-DTPA and FDG
for concurrent injection for hybrid imaging showed no changes in pH or radiochemical
purity of [18F]FDG. Therefore, simultaneous PET/MRI is promising as it gives the ability
to accurately measure complementary aspects of inflammation through both modalities,
specifically cardiac inflammation alongside diffuse fibrosis and this has potential
application in remote myocardium.
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Chapter 3

3

Tracking the progress of inflammation with PET/MRI in a
canine model of myocardial infarction
3.1

Introduction

After a myocardial infarction (MI), patients remain at risk of adverse events, including
heart failure1. Risk factors for these adverse events include infarct size2,3 and extent of
microvascular obstruction4. Both are independent predictors of left ventricular
remodeling. Inflammation also plays a key role in the response to infarction and its
evolution will play a key role in determining how the left ventricle remodels. Both MRI
and FDG-PET may provide insights into the evolution of myocardial injury and
inflammation.
Using MRI, T1 maps can be obtained and used to measure the extra-cellular volume, an
indicator of tissue edema, a common accompaniment of inflammation. ECV is elevated
within infarcted tissue post-MI, starting in the first few hours5. However, little is known
about the ECV in remote non-infarcted, non-ischemic myocardium as the left ventricle
remodels 6. In such tissue, fibrosis, cellular inflammation and edema may evolve
gradually which would result in a slow increase in ECV, which might only be measurable
over extended periods of time (months)7,8.
In addition to defining the extent of irreversible injury, the delayed enhancement protocol
also provides a volume measure of microvascular obstruction within the infarct which we
designate hereafter as Infarcted Obstructed Tissue or IOT. IOT has very compromised
blood flow with reduced tracer delivery. Little is known about the ECV in the IOT and
how it changes in time post-MI.
In order to quantitate ECV in remote tissue (RT), infarcted tissue excluding any region
with significant microvascular obstruction, Infarcted Non-Obstructed Tissue or INOT,
and IOT, single-slice breath hold T1 maps need to be acquired spanning the entire heart9–
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11

. However, this requires acquisition during which the concentration of GBCA in the

blood and tissue should not be changing significantly, as it normally would following a
bolus injection9–11. However, it has been known for some time that a bolus injection
followed by a constant infusion of GBCA, given the correct timing and dose distribution
between the bolus and constant infusion, achieves relatively rapid constant blood
concentrations9–12. Despite this, few studies have investigated just using a prolonged
constant infusion to measure ECV in the RT, INOT and IOT13.
Post-MI, cellularly mediated inflammatory processes clear out myocardial cellular debris
and stabilize the region of infarction with scar tissue. When using FDG to image
macrophage mediated cardiac inflammation, an important consideration is effective
suppression of the glucose uptake by cardiomyocytes to get an accurate picture of
inflammation, without the confounding effect of myocardial glucose uptake. This is
generally achieved with one or more of: fasting, a high-fat diet, heparin injection, and in
animals, a lipid infusion14. In addition to the concern regarding suppression of myocardial
glucose uptake, an additional concern with FDG PET imaging in acute MI is the
potential effect of IOT on the apparent inflammation profile: lower FDG activity in the
center of the infarct (i.e. the IOT) may be primarily the result of reduced delivery of this
tracer as a result of the severely compromised flow. Since myocardial infarction patients
with IOT have poorer outcomes it is imperative to be able to accurately quantitate the
inflammatory processes within this region (without the confounding effects of
compromised tracer delivery), in order to plan future interventions to improve prognosis.
Previously, a constant infusion has been used in the brain to penetrate the ischemic region
post-stroke15. We propose that a constant infusion of Gd-DTPA and FDG would allow
penetration of the IOT to allow better characterization of the inflammatory response, both
macrophage mediated, and that associated with tissue fibrosis and edema, without the
constraints of compromised tracer delivery.
Here we have investigated the potential application of a simple combined constant
infusion of Gd-DTPA and FDG to quantitate inflammation, ECV and function in RT,
INOT and IOT in a canine model of permanent coronary artery occlusion from 3 to 42
days post-MI.
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3.2
3.2.1

Methods
Animals and Surgical Preparation

This study was approved by the Animal Care Committee of Western University. Eight
adult, female, bred-for-research hounds were used. Anesthesia for surgery and imaging
was induced using Propofol and maintained with 1.5% – 2% isoflurane. Animals
underwent imaging at baseline (n = 5), 3-4 (n = 6), 7-8 (n = 7), 14-15 (n = 6), 21-22 (n =
8) and 38-44 (n = 8) days post-MI (Figure 3-2). Due to technical difficulties, not all
animals were imaged at all time points. MI was induced by permanently placing a snare
ligature around the left anterior descending coronary artery during left thoracotomy.

3.2.2

PET Imaging

Animals were fasted between 16 and 21 hours before the start of imaging. To further
suppress myocardial glucose uptake, twenty minutes before the constant infusion of
FDG, 2000 units of heparin were administered intravenously and an infusion of 20% lipid
(Intralipid; Baxter Healthcare Corporation) at a rate of 0.25 mL/min/kg was administered
intravenously over a 50-minute period starting immediately after the administration of
heparin (see figure 3-1 for a sample image). Note that whereas in humans diet and
heparin are sufficient for 95% suppression14, in canines intralipid infusion is also needed
as we have previously reported16.

Figure 3-1:FDG uptake at day 7 post-MI, 10 minutes after the end of the constant
infusion.
This figure shows the uptake of FDG in the myocardium highlighting the infarcted area,
7 days post-MI, 70 minutes after the start of the infusion. From left to right, there are a
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T1 map, a T1 map overlaid with FDG PET and PET only. It should be noted that there is
some uptake within the entire myocardium and not just the infarct (red arrow). A longer
washout time would likely eliminate a large portion of this. The method of suppression
has also been previously used and found to be adequate in this animal model with a bolus
injection99. This image also highlights the incision site (orange arrow) which shows that
macrophage FDG uptake is not affected by suppression of myocardial glucose uptake.
A 60-minute constant infusion of both FDG (0.17 MBq/min/kg; Fludeoxyglucose (18F)
Injection, produced in-house at the Lawson Cyclotron Facility) and Gd-DTPA (0.004
mmol/min/kg for a total dose of 0.24 mmol/kg, Magnevist; Bayer Inc.) was started
simultaneously with the beginning of the list mode PET acquisition. In addition to the 60minute infusion, the PET acquisition was extended to a further 10-minute washout in 3
dogs and a 30-minute washout in 5 dogs. The PET data was reconstructed in 3-minute
frames using a 3D Ordered Subset Expectation Maximization reconstruction (3 iterations,
21 subsets, 172 x 172 x 127 matrix size, zoom of 2 and 4 mm Gaussian filter). MR-based
attenuation correction was achieved using a two-point Dixon MRI sequence and
segmented into water, fat, lung and air with constant attenuation coefficients for each
tissue17. The PET voxel size was 2.09 x 2.09 x 2.03 mm.

3.2.3

Cardiac MR imaging

MR imaging was started 60 minutes prior to the beginning of the constant infusion.
Sequences included short axis cine stacks of the left ventricle synchronized to the ECG
signal (true fast imaging with steady-state free precession (TrueFISP), slice thickness 6
mm, 256 x 216 voxels, voxel size 1.09 x 1.09 mm, ~12s acquisition time, based on heart
rate) where each slice was acquired during a breath hold; a 3D T1 weighted image (ECG
triggered Inversion Recovery sequence with navigator echo for respiratory gating, 256 x
200 x 112 voxels, voxel size 0.625 x 0.625 x 0.9 mm, ~4 minute acquisition time, based
on heart and respiratory rate); T1 maps (ECG-triggered modified Look-Locker inversion
recovery sequence, slice thickness 6 mm, 256 x 144 voxels, voxel size 1.09 x 1.09 mm,
~12s acquisition time, based on heart rate) in a single breath hold to acquire 2-chamber
and 4-chamber views of the heart (Siemens Work In Progress). In 7 animals, T1 maps
and 3D T1 weighted images were acquired in 10 minute intervals. In the other animal, 4-
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chamber view T1 maps were acquired every 3 minutes and a 3D T1 weighted image was
acquired 70 minutes into the PET scan (i.e. 10 minutes after the infusion was stopped).
See figure 3-2 for details on the timing of both the MRI and PET data acquisitions.

Figure 3-2: Experimental Protocol.
After the subject was setup in the MR scanner, MRAC, localizers, pre-contrast images
and cine images were acquired. During this time, heparin was injected and lipids where
infused. Then, a constant infusion of Gd-DTPA and FDG was started and T1 maps and
3D T1-weighted images were acquired in conjunction with FDG list-mode data.

3.2.4
3.2.4.1

Data Analysis
Regions of Interest

Regions of interest (ROIs) were manually drawn onto the final Gd-enhanced T1 map
which was then automatically transferred to all other T1 maps. The ROIs outlined were
the IOT, the INOT, two samples of RT, and the blood pool. Note that the IOT only
included tissue with microvascular obstruction and the INOT was all other infarcted
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tissue, excluding the IOT. The 2D ROIs were then also transferred to the corresponding
slice of PET data. Figure 3-3 shows the selection of the three regions of interest (RT,
INOT and IOT) and the selection of the blood pool region within the left ventricular
cavity all taken 10 minutes after the 60-minute constant infusion. Manual adjustment of
some images in the series was applied to offset changes in heart position. Edges were also
avoided when drawing ROIs to minimize partial volume averaging from voxels at the
myocardial-blood pool border.

Figure 3-3: Region of interest selection post-MI on a 2-chamber T1 map.
Glucose metabolism and extracellular volume (ECV) measurements were calculated at
four separate regions (two in remote tissue (RT), one in infarcted not obstructed (INOT),
excluding tissue with microvascular obstruction, and one in infarcted obstructed tissue
(IOT)).

3.2.4.2

Glucose Metabolism

FDG concentration curves of all ROIs were fit to the Patlak model18 as discussed in
section 2.2.4.
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3.2.4.3

Extracellular Volume Fraction

ECV maps calculated at the 60-minute time point in the constant infusion were used to
compare changes over time. For the estimation of ECV equilibrium was assumed to be
reached when the difference in ECV between acquisitions was less than 5%, as done by
White et al23. 76 out of 868 T1 maps could not be analyzed due to excess noise and were
excluded. ECV was calculated as discussed in section 2.2.3.

3.2.4.4

Volumes of IOT and INOT

To determine the volume of the IOT and INOT, gadolinium-enhanced 3D T1 weighted
images were segmented by a single observer using the 3D Slicer Segment Editor
(http://www.slicer.org/)24. Thresholds were determined for IOT, INOT and RT and drawn
using the Threshold Paint function. The threshold was set for each experiment to exclude
the IOT and occasionally had to be adjusted between slices.

3.2.4.5

MRI Measurement of Heart Function

Using Slicer to analyze the ECG triggered short axis TrueFISP image series, the blood
pool can be segmented. A single operator defined the blood pool throughout the series
and determined the phases of the cardiac cycle with the highest and the lowest blood
volume. These were defined as the end diastolic volume (EDV) and end systolic volume
(ESV). The ejection fraction (EF) was calculated using the equation,
𝐸𝐹 =

𝐸𝐷𝑉 − 𝐸𝑆𝑉
∙ 100%.
𝐸𝐷𝑉

These results were compared to the automatic segmentation generated with commercial
cardiovascular image analysis software, circle cvi42 (Circle Cardiovascular Imaging Inc,
Calgary), and were found to be within 5% when the same number of short axis slices
were used. As circle cvi42 failed in a number of sets of data we report values from Slicer.
Slices were excluded due to poor image quality, if the aorta was visible or if they were
past the apex.
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3.2.4.6

Statistics

Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla,
CA). All data is presented as mean  standard error of the mean. Repeated-measures
analysis of variance (ANOVA) was performed on the days post-MI, prior to washout and
following washout. Comparison of differences in RT, INOT and IOT, as well as during
washout of Gd-DTPA, was assessed with paired and unpaired two-tailed t tests. A pvalue of <0.05 was considered to be statistically significant. Corrections for multiple
comparisons were performed using a Bonferroni multiple comparison test.

3.3
3.3.1

RESULTS
Volume of IOT and INOT

Figure 3-4 shows the T1 maps determined every 10 minutes for one dog.
Penetration over time into the IOT can be seen. ROIs were drawn on the 73-minute map
to allow for some washout from the blood pool. Measuring the volume of the INOT
showed a decrease over time in all animals with a mean starting value of 15174 mm3 at
day 3 and a final value of 4939 mm3 at day 43, as shown in figure 3-5. Statistical
differences were observed starting at day 14 (p = 0.014) and then also on day 21 (p =
0.0031) and day 43 (p = 0.0003).
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Figure 3-4: 2-Chamber T1 maps throughout the constant infusion at day 7.
This image shows the influx of tracer into the IOT (blue arrows) and INOT (yellow
arrows).

Figure 3-5: Change in INOT Volume over Time.
The INOT volume starts at its highest at day 3 and decreases over 42 days in all 8
animals. Day 3: n = 7, Day 7: n = 7, Day 14: n =5, Day 21: n = 8, Day 42: n = 6.
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3.3.2

Extracellular Volume

There was a significant increase in RT at minute 60 on day 14 (p=0.0336) and day 21
(p=0.0205) post-MI compared to the baseline healthy myocardial ECV as shown in figure
3-6. There was no significant difference in RT ECV on day 3 (p=0.50), day 7 (p=0.086)
and at day 40 post-MI (p=0.0597) relative to the baseline myocardial ECV.

Figure 3-6: ECV in remote tissue post-MI.
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a) ECV (mean ± SEM) varies in the days following MI in the RT over the duration of the
scan using the constant infusion protocol. b) ECV values for each canine at each
respective day post-MI in RT 60 minutes into the scan, at equilibrium, prior to washout of
Gd-DTPA. * represents a significant difference of (p<0.05)

Figure 3-7: ECV measurements pre- and post-MI in all tissue types.
ECV measurements were calculated in eight canine subjects measured every 10 minutes
for up to 90 minutes after starting the constant infusion of Gd-DTPA. ECV was
calculated in RT, INOT and IOT at days 3, 7, 14, 21 and 40 post-MI and prior to MI.
Data represented are mean ± SEM. Constant infusion of Gd-DTPA was terminated at 60
minutes followed by 30 minutes of washout. Only one canine showed an IOT at day 21
and no IOT was seen for any canines 40 days post-MI. Figure 3-7 shows how the
measured ECV varies with time for RT, IOT and INOT. Clearly RT reaches equilibrium
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as quickly as seen in the normal myocardium measured at baseline with no change
during washout. The measurement in the INOT reaches equilibrium well within the 60
min constant infusion at all days except at day 3. The measurement in the IOT does not
reach equilibrium except perhaps at day 7, though there was still a significant difference
between the 50 minute and 60 minute timepoints. It is clear that the measurement of ECV
is not accurate during washout for either INOT or IOT, independent of time, post-MI.
As shown in Figure 3-7, ECV was significantly elevated in the INOT myocardium at
minute 60 compared to RT myocardium at all time points post-MI (days 3, 7, 14, 21 and
40) (p<0.001).
In the INOT at day 3, there was a significant increase at minute 60 compared to minute
50 (p=0.024). At all other days post-MI there was no significant difference between
minute 60 and minute 50 (day 7: p=0.062; day 14: p=0.39; day 21: p=0.47; day 40:
p=0.11).
In the IOT, there was no significant difference in ECV at day 3 at minute 50 and minute
60 (p = 0.17). There was a significant difference between minute 50 and 60 at day 7
(p<0.01), however, at all other time points there was an insufficient number of canines
with an IOT to do proper analysis (N=3 for day 14, N=1 for day 21, N=0 for 40 days).

Figure 3-8: ECV measurements in the INOT post-MI.
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This figure shows ECV values for the INOT tissues for all canines post infarction as a
function of 60 minute constant infusion followed by 30 minutes of washout. Measured
ECV is increased during the washout period of Gd-DTPA.
Figure 3-8 shows ECV values for the INOT tissues for all canines post-MI as a function
of 60-minute constant infusion followed by 30 minutes of washout. The measured ECV is
significantly increased during the washout period of Gd-DTPA (see figure 3-9). This was
also seen for the IOT tissue at day 3 at 70, 80 and 90 min of washout and at day 7 at 90
min while at days 14, 21 and 40 there was insufficient data for analysis as the IOT tended
to resolve into INOT.

Figure 3-9: ECV in the INOT 3 days post-MI.
Measured ECV in the INOT three days following myocardial infarction at minute 60,
compared to times following washout (10, 20, 30 minutes into washout, p = 0.0035, p =
0.0181, p = 0.0468, respectively). * represents a significant difference of p<0.05.
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3.3.3

Patlak Parameter Estimates
Figure 3-10 shows the Ki for all 8 animals in remote myocardium as a function of

time post MI. Although it appears that there was an increase in some animals early postMI, no significant changes were seen (day3: p=0.38; day 7 p = 0.32; day 14: p = 0.11;
day p = 21: 0.19; day 43: p = 0.63).

Figure 3-10: Remote tissue Ki pre- and post-MI.
Remote Ki shows no significant difference over time though it appears as though there
may be a rise over the first week. This plot shows the mean and interquartile ranges (box)
and the maximum and minimum values (whiskers).
Figure 3-11 shows the glucose metabolism for the INOT, Ki, as a marker of glucose
metabolism, significantly exceeds baseline (0.00514+/- 0.00045) at all points other than
day 43, when glucose metabolism returns to the baseline value. While day 3 is not
significantly different from day 7, it is higher than all other values, showing that the
inflammatory response appears largest within the first week of infarct. This decrease over
time appears to be linear with an r value of 0.918 (p = 0.0278).
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Figure 3-11: Ki in INOT post-MI.
INOT Ki decreases linearly (dashed lines indicate confidence interval) over time,
returning to pre-infarct values (0.00514+/- 0.00045) at day 43. Ki in the INOT is
significantly different from day 3 at day 14 (p=0.0143), day 21 (p=0.0031) and day 42
(p=0.0003).
The distribution volume in the INOT, calculated with the Patlak model, also undergoes
significant changes post-MI, where days 7 (p = 0.0199), 14 (p = 0.0015), 21 (p = 0.0001)
and 42 (p < 0.0001) are significantly higher than day 3 as shown in figure 3-12.
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Figure 3-12: Distribution volume (y-intercept) calculated using the Patlak model in
the INOT.
Days 7 (p=0.0199), 14 (p = 0.0015), 21 (p = 0.0001) and 42 (p < 0.0001) are
significantly higher than baseline though a lot of variation was seen on day 7.
Glucose metabolism in the IOT is increased at days 3 (p = 0.0332) and 7 (p = 0.0042)
relative to baseline. There were not enough values for subsequent days to test
significance, although in the remaining animals, it does appear to stay elevated.

92

Figure 3-13: End-systolic volume, end-diastolic volume and ejection fraction over
time post-MI.
As in human patients, there is an initial drop in ejection fraction (p=0.0013) which then
recovers in the following week and remains near baseline. This initial decline can be
explained by an increased ESV (p = 0.0127) with steady EDV.

3.3.4

Measurements of Cardiac Function
Figure 3-13 shows the ejection fraction (EF), end-diastolic volume (EDV) and

end-systolic volume (ESV) for all animals. A sharp decrease in ejection fraction is visible
at day 3 (p = 0.0013) before it returns to a baseline value at day 7. The end diastolic
volume on the other hand does not show a difference while the ESV increases on day 3 (p
= 0.0127).
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3.4

Discussion

In this study, we have applied PET/MR using a combined infusion of a gadolinium-based
contrast agent and FDG to assess cell-based inflammation, myocardial fibrosis, and
edema, in multiple regions of potential myocardial injury following an acute myocardial
infarction. Accurate assessment of these processes can be compromised by issues of
reduced tracer delivery, particularly within the central core of an infarction, where
microvascular obstruction can markedly reduce blood flow. A single bolus injection of
either tracer may not allow adequate penetration of these tracers into these areas of
markedly compromised flow.
Although our group has previously demonstrated that concurrent constant infusions of
Gd-DTPA and FDG can provide valid measures of ECV and 18F-FDG in normal
myocardium13, this is the first time this injection strategy has been used to investigate RT,
INOT and IOT post-MI, and sequentially over several weeks. It is evident from figure 36a) that identical ECV values in RT can be measured after 20 to 30 minutes after the
onset of a constant infusion until 30 minutes after terminating the constant infusion
implying that the GBCA must be being cleared similarly from the RT and blood.
The ECV in the INOT reached equilibrium between 50 and 60 minutes of onset for days
7 – 40 and likely did at the 60 minute time point for day 3 (see figure 3-7), demonstrating
that even with reduced blood flow in the INOT tissue, a 60-minute wash in was sufficient
to obtain accurate values of ECV. However, the 60 min constant infusion in the IOT
appears to not have reached equilibrium within the tissue and hence it is unlikely that the
estimate of ECV is accurate. The data presented in figure 3-5 and figure 3-7 at 7, 14 and
21 days suggests that ECV of IOT may actually be similar to that of INOT at the end of
the 60 min infusion. However, in the early days following infarction, at day 3, the IOT
measured ECV was comparable to RT and much lower than the measured value in INOT.
Nevertheless, compared to a bolus injection, significant penetration does occur with the
60 min constant infusion11,16,25.
Unlike RT, measurements of ECV during washout in the INOT and IOT should not be
used as they were significantly elevated at all washout time points as shown in figure 3-7,
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3-8 and 3-9. This is presumably because the blood flow is lower in the IOT and INOT
and thus dramatically reduces Gd-DTPA clearance in the myocardium compared to
blood, meaning that measured ECV appears artificially elevated26. This is the opposite to
the beginning of the scan, where the ECV is underestimated as the tracer entering the
INOT lags behind Gd-DTPA concentrations in the blood. Note that these observations
regarding achieving equilibrium in RT, INOT and IOT for GD-DTPA imply that FDG,
which was concurrently injected with Gd-DTPA, would behave similarly.
We found a significant increase in ECV in the RT at days 14 and 21 post-MI, but not at
days 3 and 7. Increases in ECV in RT may reflect more generalized but less intense tissue
edema and/or an early fibrotic response, not just limited to the area of acute ischemic
injury, a pattern that has been shown in rats8,28. Cleutjens et al. have shown increased
collagen protein deposition in rats in both infarcted and non-infarcted areas through
upregulation of type 1 and type 3 collagen mRNA transcription8. This could potentially
lead to the ECV increases that we observed post-MI8,28. At day 40, there was a p value
of 0.06 for ECV in remote myocardium. A larger sample size could potentially have
shown elevated ECV, 40 days post-MI. ECV calculation provides important, noninvasive insight into the pathophysiological mechanisms of cardiac remodeling post-MI
and may serve as an important source of diagnostic, therapeutic and prognostic decision
making10,29–31. Specifically, the change in ECV in remote non-infarcted tissue provides
strong evidence that there is a pathological process evolving in the early weeks postinfarct8,28,32. Future work is needed, such as validating this through measuring amount of
fibrosis in histological tissue samples taken from RT and comparing it to tissue from
sham treated animals.
Figure 3-13 shows that the functional assessments have a similar timeline for evolution of
heart function as human patients post-MI with reduced ejection fraction27. There is a
sharp decrease in ejection fraction at day 3 and recovery over the subsequent time points.

The decrease in the INOT volume using the 3D T1 weighted images (Figure 3-5) has
underscored a long-standing debate. This decrease likely does not represent a degree of
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tissue repair but rather reflects permanently damaged myocardial tissue, in essence,
shriveling over the days and weeks post infarct. Note this data was taken while the blood
and tissue concentrations were kept constant in the RT and to a large extent in the INOT
tissue due to the constant infusion.
The FDG results that we observed were not as consistent as the ECV results. This is
partially attributable to the lower spatial resolution of cardiac -FDG PET in comparison
to GBCA MRI, leading to potential partial volume issues in the discrimination of IOT
from INOT. However, there should be a minimal partial volume effect from the left
ventricular blood pool when assessing RT as myocardial edges were not included. As
shown in 3-9 there is a trend of an increase in Ki from baseline at days 3, 7, 14, and 21
though no significant changes were observed day3: p=0.38; day 7 p = 0.32; day 14: p =
0.11; day 21: p = 0.19; day 43: p = 0.63. These values are also similar to what was found
by Herrero et al in normal canine myocardium during suppression33. Figure 3-6b) shows
increases in ECV at days 7, 14 and potentially 43 days. Although not large effects, this
suggests that increases in ECV (potentially edema and fibrosis) is accompanied by cell
based inflammation in RT. Note how both results (Figures 3-6b and 3-10) suggest that by
43 days both are proportionately reduced. If fibrosis had developed it would seem
unlikely that it would have resolved, suggesting that perhaps edema associated with the
18

F-FDG detected inflammation may have started to resolve.

Glucose metabolism in INOT decreased with time as shown in figure 3-10, with Ki
highest at 3 days (0.0125 ml/min/g) decreasing to approximately normal tissue values by
day 43. In contrast, the Patlak analysis for INOT (see figure 3-8) showed a significant
increase in the extravascular exchangeable volume. This decrease in glucose metabolism
in the INOT suggests that the number of metabolically active macrophages is decreasing
or are being converted into M2-like macrophages, which take up less FDG than M1-like
macrophages26. It appears that the INOT experiences the highest level of inflammation
within the first week following which it declines and returns to baseline by day 43. The
IOT glucose metabolism was also significantly increased for the first week but could not
be evaluated as a separate region distinct from the surrounding INOT after that due to the
decreasing number of animals with an IOT at the later time points as there is apparent
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recovery from the initial microvascular injury. This strengthens the notion that antiinflammatory treatment would be most effective within the first two weeks, but it also
shows that the IOT may be an important factor influencing the perseverance of
inflammation, especially since glucose metabolism in that region is probably
underestimated. As we have shown here, even after the 60 min constant infusion, GdDTPA concentration was still increasing. This would suggest a corresponding increase in
FDG concentrations within the IOT and that the methodology used in the experiments
reported here underestimated the true glucose metabolic rate in the IOT.
Limitations of this study include the small number of animals, but even more so, the
small number of animals with an IOT that was sustained through the period of
observation, although this pattern of resolution of the regions of microvascular
obstruction is by itself noteworthy. Another limitation is that not all animals could be
imaged at every timepoint. While most animals had an IOT at day 3 and day 7, they
disappeared at day 14, for all but two animals. More animals would also let us study the
RT in more detail, since there is an increase in ECV on days 14 and 21 which may
correspond to an inflammatory response. We have also found that ECV may be affected
by myocardial glucose uptake suppression, i.e. is larger by 13% in healthy myocardium13.
Since all of these animals were suppressed equally, the trends found should not be
affected, but actual ECV values may be slightly lower.

3.5

Conclusion

Here we have shown rigorous longitudinal measurements of inflammation and ECV,
measured during a combined infusion of FDG and GBCA. ECV in remote myocardium at
14- and 21- days post-MI was significantly greater than at baseline. The change in ECV
in remote non-infarcted tissue provides strong evidence that there is a pathological
process evolving in the early weeks post-infarct. As the concentration of FDG in the IOT
continues to rise by the end of the constant infusion, it stands to reason that a bolus
injection of FDG would underestimate the glucose metabolism in the IOT.
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Chapter 4

4

Myocardial glucose suppression interferes with the
detection of inflammatory cells with FDG-PET in a
canine model of myocardial infarction
4.1

Introduction

Following a myocardial infarction (MI), heart failure may develop due to a number of
factors such as extent of initial myocardial injury, but is also influenced to a major extent
by dysregulation of inflammation in response to the original insult1. MRI measurements
have shown promise in detecting characteristics associated with an increased risk of heart
failure, including infarct size2,3, presence of hemorrhage and presence and size of
microvascular injury/obstruction4,5, hereafter referred to as Infarcted Obstructed Tissue
(IOT). Extracellular volume (ECV) measurements, generally associated with tissue injury
and/or edema, in particular, provides a sensitive measurement of myocardial fibrosis6.
To acquire ECV measurements with MRI, T1 maps pre- and post-contrast are required7,8.
Our group has previously shown how a constant infusion of a gadolinium-based contrast
agent (GBCA) can be used to measure ECV post-MI using a 60 min constant infusion9,10.
FDG-PET imaging allows assessment of cell-mediated inflammation but may not be able
to distinguish between uptake of the tracer by pro-inflammatory (neutrophils and M1
macrophages) vs. anti-inflammatory (M2 macrophages) cells. Further, post-MI, to make
FDG-PET specific for inflammation, uptake of FDG by non-infarcted myocardium has to
be suppressed as completely as possible so that the residual uptake of glucose is specific
and limited to that by the resident and invading inflammatory cells. In humans,
sequestration of the FDG tracer by myocardium can be achieved with fasting and the
injection of heparin11, which enhances free fatty acid utilization and decreases glucose
uptake by myocardium. In the canine model, myocyte glucose uptake suppression can be
achieved through a combination of fasting, the injection of heparin and a lipid infusion at
the time of FDG administration. However, it is not known if these suppressive techniques

103

may also affect the degree of uptake (i.e. the metabolic activity) by the inflammatory
cells (macrophages). Here, we have investigated this question in the canine model of MI.
Another issue to be considered that may affect the accurate determination of the degree of
inflammation within the infarct core is the potential partial volume effect of IOT on the
Infarcted Non-Obstructed Tissue (INOT). Due to the very compromised blood flow, PET
tracers injected as a bolus do not penetrate the IOT. As the size of the IOT is often too
small to be resolved from the INOT with PET, the presence of IOT may cause INOT
FDG uptake to appear artificially lower.
Here we report on our investigation of these potential limitations. We have evaluated the
use of a prolonged 150 min constant infusion of FDG and Gd-DTPA instead of a bolus
injection. This prolonged constant infusion allows the investigation of the effect of
suppression on uptake of FDG by inflammatory cells through the tracking of the
metabolic activity before, during and after the use of myocardial suppression techniques.
Further, this will also provide some insight into the pattern and degree of inflammatory
activity within the central IOT.

4.2
4.2.1

Materials and Methods:
Animal Preparation

The care and treatment of the animals was in accordance with the University of Western
Ontario Council on Animal Care (Animal Use Subcommittee) guidelines. The adult,
female, bred-for-research hounds weighed 18-23 kg. Anesthesia for all procedures was
induced using propofol and maintained with 1.5% - 2% isoflurane (Forane, Baxter). In
experiment one, six animals were studied at baseline (BL) twice, to determine the effect
on glucose uptake in normal myocardium of heparin alone (BL1) and of heparin
combined with lipid infusion (BL2). Combined with fasting, preliminary data indicates
that the combination of heparin and lipid is the most effective approach to suppression in
canines12. In experiment two, five of the animals from experiment one and two
additional animals, which did not undergo the procedures in experiment one, underwent a
procedure to induce a myocardial infarction. The left anterior descending coronary artery
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was permanently ligated during left thoracotomy. Five days after the surgery, the seven
animals were imaged. As only one imaging procedure was possible at five days, the
effect of suppression of glucose metabolism in the remote tissue and in the infarcted
tissue was investigated using both a heparin injection and the lipid infusion. Heparin was
administered as an intravenous bolus of 2000 units and a 20% lipid infusion (Intralipid;
Baxter Healthcare Corporation) was given intravenously over a 50 minute period at a rate
of 0.25 ml/min/kg. Since all canines were of a similar weight (20-23kg) the same dose of
heparin was used. Before each scan, the blood glucose level was measured with a
glucometer. After the post-MI imaging at 5 days, animals were given 20mL propofol and
then euthanized with an injection of KCl (30mL administered intravenously).

Figure 4-1: 150-minute constant infusion protocol.
Cine images, 3D T1 weighted images and T1 maps were acquired pre-contrast. PET listmode acquisition was started simultaneously with the constant infusion of Gd-DTPA and
FDG. Heparin injection and lipid infusion were done 40 minutes into the constant
infusion.
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4.2.2

Injection Protocol

In previous work, we have established that a simultaneous constant infusion of both GdDTPA and 18FDG is an effective approach to measure the extracellular volume (ECV) by
MRI and the glucose metabolism (MRGlu) by PET9. Unlike the typical approach using a
bolus injection, a prolonged constant infusion can be easily modelled to monitor the
effects on ECV and MRGlu of different interventions such as glucose suppression. In this
study, a 150 min constant infusion was implemented. Note that as the animals required
fasting to allow anesthesia, there is already a level of glucose suppression that varies
between animals. In the first baseline scan (BL1), a bolus of heparin was administered 40
minutes after the start of constant infusion while in BL2 and post-MI, in addition to the
heparin injection, a constant infusion of intralipid was begun and continued for 50
minutes. In all cases, the ECV and MRGlu were determined for three time intervals
during the constant infusion: from 10 to 40 min, 60 to 90 min and from 120 to 150 min.
These three time intervals have been hereafter identified as “before”, “during” and “after”
glucose suppression. During the entire 150 min constant infusion, Gd-DTPA was
administered intravenously at 4 µmol/min/kg and FDG at 0.17 MBq/min/kg.
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Figure 4-2: FDG uptake and T1 maps 5 days post-MI pre- and post-suppression.
Images were taken at 40 minutes (before suppression), 90 minutes (during suppression)
and at 150 minutes (after suppression).

4.2.3

PET/MRI Protocol

All scans were done on a 3T PET/MRI (Siemens Biograph mMR). The animals were
placed in the right lateral recumbent position and 3 electrodes were positioned on the
chest to obtain an ECG reading. The protocol is shown in figure 4-1 with the 150 min
constant infusion started at 40 min after the start of the imaging to allow for set-up and
baseline MRI acquisitions needed for the ECV calculation.
Cardiac T1 maps (4-chamber view of the heart) were acquired with a modified LookLocker inversion recovery (MOLLI) sequence13 (ECG-gated, 35° flip angle, 256 x 218
matrix size, 300 mm x 255.5 mm field-of-view, 6 mm slice thickness, 400ms repetition
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time, 1.12ms echo time) during breath hold at pre-contrast and then every 10 min after
the concurrent infusions. PET data was acquired in list-mode throughout the 150 min
constant infusion and subsequently reconstructed in 3-minute frames using a 3D Ordered
Subset Expectation Maximization (OSEM) reconstruction (3 iterations, 21 subsets, 172 x
172 x 127 matrix size, zoom of 2 and 4 mm Gaussian filter). Attenuation correction was
achieved using a two-point Dixon MRI sequence and segmented into water, fat, lung and
air with constant attenuation coefficients for each tissue. The PET voxel size was (2.09 x
2.09 x 2.03) mm3.

4.2.4

Image Analysis

Figure 4-2 shows a typical hybrid PET/MRI image set acquired at 60 and 150 min into
the 150 min constant infusion. Note that, due to the intrinsic hardware registration of the
PET and MRI subsystems, regions of infarct identified on an MRI image are
automatically registered to the PET images. However, as PET images are not corrected
for respiratory motion whereas MRI images are the registration is compromised. Image
analysis was performed using 3D Slicer (Open Source, BSD License) and MATLAB
(Mathworks, R2019a). As shown in figure 4-3, manually drawn regions of interest
(ROIs) in the 4-chamber view were used to identify the healthy myocardium and the left
ventricular blood pool for the baseline experiments. Post-MI, three regions were
identified and manually outlined by an experienced observer: remote tissue (RT),
infarcted non-obstructed tissue (INOT) and infarcted obstructed tissue (IOT). Once the
ROIs were defined, they were used as a template and copied to the rest of the images in
the series. Manual adjustment of some images in the series was applied to offset changes
in heart position. Edges were also avoided when drawing ROIs to minimize partial
volume averaging from voxels at the myocardial-blood pool border. Dynamic T1 values
(pre- and post- Gd-DTPA administration) and FDG activity concentration were measured
in each ROI.
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Figure 4-3: Regions of interest at 5 days post-MI used for the 150-minute constant
infusion protocol.
Regions of interest as defined on a T1 map 60 minutes after the start of the infusion. Red
represents the IOT, yellow the INOT and blue the RT.

4.2.5

Volumes of IOT and INOT

Volumes were manually drawn on 3D T1 weighted images by an experienced observer at
30 and 150 minutes into the constant infusion.

4.2.6

Extracellular Volume Determination

ECV was calculated as discussed in 2.2.3.

4.2.7

Glucose Metabolism

𝐾𝑖 was extracted for all ROIs in all studies as discussed in 2.2.4 and the metabolic rate of
glucose (MRGlu) was calculated by multiplying 𝐾𝑖 by the blood glucose level, taken
before the study.
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4.2.8

Histology

After the experiment 2 imaging session, the hearts from 5 of the subjects were extracted
and imaged with PET/MRI. Three regions were visually identified on the left ventricle:
the centre of infarct, edge of infarct and remote tissue. Samples were fixed, frozen and
embedded in optimal cutting temperature compound (OCT), and subsequently sectioned
at 5-6 μm thickness, as previously described19,20. Immunohistochemistry using primary
and fluorophore-conjugated secondary antibodies was conducted as previously
described19,20. In brief, tissue sections were incubated with blocking buffer in 10% serum
for 30 minutes at room temperature followed by incubation with primary polyclonal or
monoclonal antibodies for 1h at room temperature in a humidified chamber. These
antibodies were used to identify macrophages (CD68 (ab955) 1:200 dilution) and glucose
transporter 1 (Glut1 (orb157188) 1:1000 dilution). Samples were rinsed twice in
phosphate buffered solution (PBS) and incubated for 2h at room temperature with
secondary antibodies (Donkey anti rabbit 488 (A21206 ) 1:1000 dilution; Donkey antimouse 594 (A21203) 1:1000 dilution). Sections were washed twice with PBS, incubated
8 min with DAPI nuclear stain (1:1000), and mounted with ProLong Diamond antifade
(Life Technologies) to prevent the tissues from photobleaching.
High resolution images were captured with a Nikon A1R Confocal Microscope at
60x magnification using an oil immersion lens. Five random fields of view were acquired
for each of 4 tissue sections per sample with the exposure time, gain and look up tables
set the same for all tissue sections. Therefore, each sample (reported as data points in all
graphs) reflects an average of 4 technical replicates.
Images of CD68 and GLUT1 were analyzed with FIJI 1.49v, a distribution of
ImageJ software (National Institutes of Health, Bethesda). Punctate staining patterns were
quantified using the RenyiEntropy algorithm, an entropy-based approach that
distinguishes the positive punctate signals within the cells from the background. The
integrated density represents the mean intensity of the positive signal above a certain
threshold in scaled units divided by the area in pixels. The integrated density threshold
was set such that the entropies of distributions above and below the set threshold are
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maximized. Therefore, this algorithm only captured the high intensity punctate staining
patterns and did not calculate any background staining of these images.

4.2.9

Statistical Analysis

Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla,
CA). All data is presented as mean  standard error of the mean (SEM). Paired two-tailed
t-tests were performed to compare values before, during and after suppression. A p-value
of <0.05 was considered to be statistically significant. Bonferroni’s method was done to
correct for multiple comparisons when comparing multiple treatment’s means.

Results

4.3
4.3.1

Effect of Suppression on metabolic rate of glucose
consumption

As shown in figure 4-2, glucose suppression using heparin and an infusion of intralipid
has the desired effect of suppressing remote myocardial tissue and thereby highlighting
the inflammatory activity within the infarcted zone. As heparin was injected at 40
minutes and the lipid infusion was started at the same time, suppression was seen on the
FDG time-activity graphs at 60 minutes. At 150 minutes, there is a higher concentration
of FDG in the infarcted zone compared to the 60 minute time point. This is also
highlighted by the graph in figure 4-4, showing the FDG uptake quantitatively over time
in one animal.
When we analyse the metabolic rate of glucose in all tissues using Patlak graphical
analysis, a significant difference is seen from before glucose suppression to during, with
a reduction in the metabolic rate, and after, as shown in figure 4-5. Using both heparin
injection and lipid infusion (BL2), a significant difference is seen in healthy tissue from
before to during and after suppression. However, using heparin only (BL1) this effect is
not as large, with significance only reached between before and during but not before and
after suppression. This may mean that heparin alone is not as effective in suppressing
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glucose metabolism as the combination of heparin and lipid infusion. Post-MI, MRGlu in
both INOT and RT are significantly reduced as shown in figure 4-5. Before suppression
there is no significant difference in MRGlu between INOT and RT but during and after
suppression, MRGlu is significantly higher in the INOT.

Figure 4-4: FDG activity concentration over the course of a 150-minute constant
infusion in one representative animal.
During the first 60 minutes, INOT and remote tissue rise at almost the same rate but
when suppression takes effect, the slope of the remote tissue is strongly reduced while in
INOT it is only reduced slightly. Vertical bars show the time during which lipid infusion
is applied.

4.3.2

Effect of suppression on extracellular volume

As shown in figure 4-6 with either heparin alone (BL1) or heparin with lipid infusion
(BL2), there is no significant difference in ECV measurements in healthy tissue between
before, during and after, highlighting that neither heparin nor intralipid infusion affect
ECV measurements. Post-MI, there is also no significant effect of suppression in the RT
and INOT on ECV.
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Figure 4-5: Metabolic rate of glucose consumption at baseline and 5 days post-MI.
Metabolic rate of glucose consumption decreases in all cases when suppression is
applied. However, when using heparin only (BL1), there is no significant difference from
before suppression to after. It should also be noted that post-MI, MRGlu does not
decrease as much as in the remote tissue even though their starting points are similar. No
significant differences were found between during suppression and after suppression.

Figure 4-6: Suppression of myocardial glucose uptake does not affect ECV at 5 days.
There is no significant difference between suppression by heparin only and heparin and
lipid infusion. Suppression of myocardial glucose uptake did not significantly affect ECV.
It should be noted that the ECV in the INOT was approximately twice as large as in
remote tissue.
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4.3.3

Penetration of infarcted obstructed tissue

As shown in figures 4-2 and 4-7, there is a degree of penetration of Gd-DTPA, and
therefore likely FDG, into the IOT. It appears that the FDG activity in the IOT is rising
linearly over the course of the infusion. The apparent size of the IOT is also greatly
reduced in the three animals with an IOT (69%, 93% and 93% reduction in IOT volume
from 30-150 min) when the measurement after 30 min of CI is compared to the end of the
constant infusion i.e. at 150 min due to progressive penetration of the tracer into the areas
of most compromised flow during the course of the infusion.

Figure 4-7: IOT and INOT volume 5 days post-MI.
While only three animals had an IOT, in these animals, the IOT volume decreased by
69%, 93% and 93%, showing some penetration over time of the IOT. INOT volume on the
other hand remained the same.

4.3.4

Histology

As shown in figure 4-8, there was a significant increase in CD68 expression in the centre
of the infarct compared to the edge of the infarct and in the remote tissue which were not
significantly different. There was no difference seen in GLUT1 expression for all regions.
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Figure 4-8: GLUT1 and CD68 expression 5 days post-MI.
No significant differences were seen in the GLUT1 expression in the center of infarct,
edge of infarct and remote tissue. However, CD68 expression was higher in the center of
infarct than at the edge of infarct and in the remote tissue. Representative histological
images of each are shown on the left.

4.4

Discussion

Myocardial glucose suppression has previously been assumed to only affect
cardiomyocytes but not inflammatory cells such as macrophages21. This has been largely
an unquestioned assumption in publications dealing with protocols associated with the
needed suppression of FDG uptake in normal myocytes in order to visualize
inflammation in diseases like cardiac sarcoidosis. Here we show that there is a significant
effect of suppression “within” infarcted tissue (figure 4-5), suggesting either an effect of
suppression on macrophages or alternatively, the presence of a significant volume of
viable myocytes in the infarcted region, that are subject to the same metabolic effects of
suppression on the cardiomyocytes within the non-infarcted regions. Considering the
large increase in extracellular volume (approximately double) within the infarcted region,
it is unlikely that there is a large presence of viable myocytes. This potential effect of
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suppression on inflammatory cells may make FDG-based PET imaging less sensitive to
inflammatory activity, highlighting the need for tracers that are not only specific for the
presence of inflammation but whose uptake is not confounded by the metabolic state
present at the time of injection and during the period of imaging.
The difference in MRGlu results at baseline supports our previous work9 showing that, in
the canine model, to achieve adequate suppression of myocardial glucose uptake,
combining a heparin injection with lipid infusion performs better than a heparin injection
alone. However, the variability of FDG uptake in normal myocardium due to fasting
alone, prior to anaesthesia, makes it difficult to compare values before glucose uptake
suppression to after suppression.
ECV measurements, on the other hand, do not appear to be affected by heparin or lipid
infusion with no significant difference seen within each baseline scan but also not
between BL1 and BL2. In a previous study, we found a trend towards higher ECV with
the use of heparin and lipid infusion when compared to fasting alone when the ECV was
measured at 14 and 21 days post MI 9. This implies that this increase seen was not related
to an artifact associated with changes in haematocrit due to the constant infusion
protocol.
While only three animals had a visible IOT, in these animals the apparent IOT volume
decreased by 69%, 93% and 93% after a 150 minute constant infusion of Gd-DTPA. Not
only does this show that Gd-DTPA is slowly penetrating into the IOT (the concentration
will slowly continue to increase until the extravascular volume is “filled”) but it also
suggests that measurement of inflammation in this region using PET imaging is possible
if corrections are developed for the impact of this slow delivery of FDG. Due to the
resolution of PET, the IOT also presents a major partial volume problem for the INOT
and penetrating it with the tracer would make quantification of inflammation within the
INOT less affected by partial volume artefacts and therefore more accurate.
Histology shows that GLUT1 expression is the same in infarcted tissue as in remote
tissue; this similarity lines up well with the MRGlu before suppression in RT and INOT
which is also not significantly different. While histology shows GLUT1 expression to be
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the same in the infarct as in the remote tissue, the CD68 expression is more than twice as
high in the infarct as in the remote tissue. Since ECV has gone up, there must be more
GLUT1 receptors expressed per cell in macrophages at 5 days post MI. Previously,
GLUT1 has been shown to be overexpressed in macrophages but this has not been
compared to myocytes22. Alternatively, fasting may have reduced expression in the
myocytes. It would be interesting to compare the numbers of Glut1 receptors at later
times post MI when the number of M2 macrophages are dominant over the M1’s that are
predominantly present at 5 days post MI. The high ECV also explains the high CD68
expression as more cellular debris would lead to more macrophages. CD68 has
previously been shown to be increased in infarcted and remote tissue post-myocardial
infarction23.
Limitations of this study include that the effect of fasting may be variable as we have
shown previously9 and the small number of animals, specifically the small number of
animals with an IOT. With this small number of animals with IOT, it is impossible to
determine whether the volume reduction is significant. It also means that glucose
metabolism in the IOT could not confidently be determined.

4.5

Conclusion

This research suggests that inflammatory cells are affected by myocardial glucose uptake
suppression in a canine model of myocardial infarction. This problem may be solved by
using different tracers that do not require glucose suppression.
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Chapter 5
Conclusions, Limitations and Future Directions

5

5.1

Conclusions and Future Direction

In this final chapter, the main objectives of this thesis will be discussed and summarised.
Additional limitations will be outlined and future directions will be discussed. The
overall impact of this research on the field of PET/MRI in myocardial infarction imaging
will also be considered.

5.2

Research Objectives

Post-myocardial infarction, patients are at risk of adverse remodeling leading to heart
failure, in part due to an ongoing, dysregulated pro-inflammatory response. An imaging
method is needed to determine whether patients are at risk of or currently undergoing a
dysregulated pro-inflammatory response in remote, peri-infarct and infarcted tissue. The
objectives of this research were to a) determine that it is safe to combine gadoliniumbased contrast agents and FDG, b) evaluate whether a constant infusion could be used to
achieve the same glucose metabolism results at baseline as a bolus injection, c)
longitudinally examine the use of a constant infusion post-MI and d) determine the
effects of myocardial glucose suppression on extracellular volume and glucose
metabolism in infarcted and remote tissue.

5.3
5.3.1

Summary of Individual Chapters
Chapter 1: Hybrid PET/MR imaging in myocardial
inflammation post-myocardial infarction

Chapter 1 describes the background for the following chapters. It highlights hybrid
PET/MR imaging as an emerging imaging modality which is more than just a sum of its
components, PET and MRI. PET and MRI can separately image many aspects of
inflammation such as glucose metabolism (PET) and perfusion (MRI). However, hybrid
PET/MRI may be able to further this goal through innovative combinations of these
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modalities. One such example is using a dual constant infusion of the gadolinium-based
MR contrast agent and the PET tracer, allowing for easier kinetic modeling and
simultaneous measurements of glucose metabolism and extracellular volume. Combined
reconstruction may also allow for enhanced motion correction of PET imaging, lowering
the partial volume problems associated with it1.

5.3.2

Chapter 2: Simultaneous measurements of myocardial
glucose metabolism and extracellular volumes with hybrid
PET/MRI using concurrent injections of Gd-DTPA and
[18F]FDG

Chapter 2 sets the groundwork for chapters 3 and 4 as well as future work. First of all, it
had to be ensured that it is safe to combine Gd-DTPA and FDG or gadopentetic acid and
FDG in one syringe. Both gadolinium-based contrast agents were tested to have an
example of a linear and a cyclic chelator. There was no difference in pH, appearance or
chromatography results between the original sample and the working sample, showing
that there is no chemical change in the mixture and it is therefore safe to use. Once that
was determined, the next step was to compare glucose metabolism and extracellular
volume at baseline with different injection and suppression strategies. The different
injection types were constant infusion only, bolus injection only and bolus injection
followed by constant infusion. These were done once with suppression by heparin
injection and lipid infusion and once with only fasting for glucose suppression. In all
cases, the same amount of Gd-DTPA and FDG were administered. No significant
differences were seen between the different injection methods, though ECV was
significantly higher (13%) in the suppressed group than in the unsuppressed group.
Overall, these similarities show that both bolus injection followed by a constant infusion
and constant infusion only are good alternatives to the clinically used standard of care
bolus injection2.

5.3.3

Chapter 3: Tracking the progress of inflammation with
PET/MRI in a canine model of myocardial infarction

In chapter 3, a potential application of the constant infusion is examined. The IOT has
been historically difficult to examine due to the extremely low blood flow. The 60 min
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constant infusion protocol was applied here in order to evaluate if it would be superior in
penetrating this region. Remote tissue has also been chronically understudied and was
therefore examined as well. Eight animals were scanned before induction of a myocardial
infarction and then again at days 3, 7, 14, 21 and 42 after the surgery with the goal of
measuring the glucose metabolism and extracellular volumes in INOT, IOT and RT. IOT
and INOT volume as well as cardiac function were also measured. While penetration into
the IOT is shown, only 3 animals presented with an IOT region which limited the ability
to assess a 60 min constant infusion. ECV was significantly elevated in the RT on days
14 and 21, showing that there may be inflammation mediated extracellular edema/fibrosis
within that tissue. This research also provided the first in-depth look at inflammation
using PET/MRI over the first 6 weeks post-MI and provided some evidence of shrinkage
of the apparent IOT volume over the course of a 60 minute constant infusion of contrast
agent3.

5.3.4

Chapter 4: Myocardial glucose suppression interferes with
the detection of inflammatory cells with FDG-PET in a canine
model of myocardial infarction

While a 60 minute constant infusion reduced the apparent volume of IOT (maximum of
50% reduction) seen on MRI, the effect was not large enough to eliminate partial volume
effects on PET. In order to further reduce apparent IOT volume, a 150 minute constant
infusion was used to penetrate the IOT. To test the effects of suppression of myocardial
glucose uptake, 40 minutes into the constant infusion of Gd-DTPA and FDG, heparin
was injected and a lipid infusion was started. ECV was unaffected by glucose suppression
in RT and INOT at 5 days post-MI, which was consistent with the findings shown in
chapter 3 at 7 days post-MI. Metabolic rate of glucose, on the other hand, was decreased
in RT and INOT. The high ECV in the INOT (twice the volume fraction of remote tissue)
suggests that the tissue is severely and irreversibly injured, with few or no viable
myocytes. As such, the decrease in MRGlu in the INOT (figure 4-5) is likely an effect of
glucose suppression primarily on macrophages. This finding highlights the need for
tracers which do not rely on glucose suppression to image inflammation, e.g. PET tracers
that target TSPO overexpressed in activated macrophages such as 18F-FEPPA. The
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efficacy of 18F-FEPPA to image inflammation will have to be shown in a canine and
human study, both of which are in progress.

5.4

Limitations

The major limitation of this work is the small number of animals, particularly the number
of animals with microvascular obstruction. One of the goals of this research was to
investigate the inflammatory response in the regions with microvascular obstruction but
the small number of animals made this impractical. Using an animal model with larger
infarcts and/or reperfusion injury, such as a 3-hour occlusion followed by reperfusion,
may be more likely to cause the animal to have regions of microvascular obstruction4.
In these studies, a linear gadolinium chelate, Gd-DTPA, was used. While these linear
chelates have been largely discontinued due to the potential for gadolinium toxicity, their
use should not affect results. There has been no evidence in literature that results obtained
with linear chelates are inconsistent with cyclic chelates5.
Histology was only conducted for one of the studies (Chapter 4) on day 5 post-MI.
Histology at every timepoint would be ideal since it could be used to confirm the number
of macrophages in all tissues to compare to ECV and glucose metabolism results in
chapters 2 and 3. More histological data would also allow for additional information such
as apoptosis to be obtained. In addition to histology, blood sampling to look for heart
failure markers such as TNF-α or BNP would be a great addition to these studies since it
would allow for further determination about whether the animals were moving into heart
failure rather than only looking at the MRI results for cardiac function.
FDG data was only analysed in two dimensions, to align with the T1 maps. However, 3D
data is available due to the nature of PET. Analysing this data in 3D would be a better
way to analyse this data, simply because there would be more data. It would not however,
line up with the T1 maps and would lead to further difficulties regarding region of
interest selection as that is best done on the T1 maps. The constant T1 values during a
constant infusion, as shown in chapter 2, could resolve this problem since 3D T1 maps
could be acquired during the equilibrium time of gadolinium concentration.
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ECV was calculated with the assumed haematocrit of 0.45. It would be ideal to collect
blood at every point at which ECV is calculated, i.e. every 10 minutes, or at least before
the scan, during the scan but before the lipid infusion, during the lipid infusion, after the
lipid infusion and at the end of the scan (in terms of the 150 minutes infusion).

5.5
5.5.1

Future Work
The role of the remote tissue

Chapter 3 shows a significant difference in ECV in the remote tissue at days 14 and 21.
While this likely shows damage due to inflammation, the FDG results were inconclusive.
A further study with more animals and a focus on this region may be able to determine
whether this is inflammation-related, especially if animals were sacrificed and tissue
harvested for histology. For example, in a study with 12 animals with acute MI, 6 could
be sacrificed at day 7 to obtain tissue samples from the acute inflammatory phase and the
other 6 would go on to day 21 with imaging at days 3, 7, 14 and 21. Important stains
would be CD68 for macrophages and neutrophils, Oil-Red O for lipid-laden macrophages
(to examine fat infiltration)6, and Haematoxylin-Eosin for apoptosis. Some research also
suggests that M1 and M2 macrophages could be distinguished when staining with both
CD68 and CD163 but this is still controversial7.
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Figure 5-1: Comparison of Ki in IOT and INOT.
While the number of animals with IOT is too small to be certain, there is no significant
change over time in Ki in the IOT tissue while the INOT decreases with significant
differences from day 3 observed at days 14, 21 and 43.

5.5.2

The role of the microvascular obstruction in left ventricular
remodelling

One of the main problems of PET/MR imaging is that it is difficult to penetrate the
microvascular obstruction. Due to this, the extent of inflammation within that region is
currently unknown. Chapter 3 showed the timeline of inflammation in the INOT but not
the IOT. Shown in figure 5-1 are preliminary results where there is no significant change
in IOT Ki over time. It would be interesting to see whether an increased number of
animals with MO would show a similar trend or clarify the difference between the two
curves. However, as discussed before, the number of animals with IOT is too small to be
certain. Using a similar workflow to what we have used so far, but with an animal model
that has a high chance of MO, perhaps reperfusion injury, would allow differences
between the IOT and INOT to be brought to light. If there is indeed a difference in the
timeline of inflammation in the IOT and INOT then it raises the question of whether the
higher inflammation in the IOT affects inflammation in the INOT or the RT. It may be
possible to focus treatment on the IOT or at least to assess the risk of heart failure in these
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patients more accurately though better PET resolution, perhaps through hybrid
reconstruction8, may be necessary.

5.5.3

Interventions during a constant infusion

In chapter 4, a 150 minute constant infusion was used with suppression of myocardial
glucose uptake started 40 minutes into this infusion. This had a drastic effect on
myocardial glucose uptake while ECV was unaffected. This principle could be expanded
to other treatments or tracers, similar to a stress/rest scan. For example, during a 10
minute constant infusion of 13NH3, adenosine could be injected at 5 minutes and
differences in the slope of tracer uptake would show which areas have a perfusion defect
during rest and stress. While it would be difficult to use this approach with a short-lived
tracer such as NH3, it may be optimal for others such as 18F-Flurpiridaz9 where the long
half-life prevents stress-rest scans. It could also be expanded to a fatty acid tracer such as
11

C-palmitate10 where glucose or heparin could be injected partway into the scan.

5.5.4

Patient Study

In addition to the results shown in these studies, a patient study is underway. In this
study, a total of 30 patients will be examined. The study consists of two imaging timepoints, the first at 7-14 days following acute MI and the second at three months following
MI. Before the first imaging session, patients are asked to follow a high fat diet plan and
a 12-hour fast. Before imaging, a glucometer reading is taken. During the imaging
session, patients receive perfusion imaging by 13NH3 PET with cine MRI to determine
cardiac function. This is followed by a 60 min break. During this break, patients receive
two doses of heparin to suppress myocardial glucose uptake in conjunction with the
aforementioned high fat diet and fast. Once patients are back in the PET/MRI, precontrast T1 and T2 maps are acquired. Then, the patients receive a combined bolus
injection over 2 minutes of gadobutrol (Gadovist) and FDG followed by a 30 minute
constant infusion of the same for a total dose of 0.2 mmol/kg Gadovist and 5 MBq/kg
FDG. T1 maps are acquired in 2-chamber and 4-chamber views every 10 minutes for the
first 40 minutes and then again between 50 and 60 minutes. PSIR images are acquired
between 40 and 50 minutes. The follow up scan at 3 months post-MI is MRI only and
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uses cine MRI to determine heart function and T1 maps before and after gadobutrol to
determine extracellular volume.

Figure 5-2: T1, T2, FDG and NH3 images in acute MI in patients.
This figure shows, from left to right, the T1 map, T1 map with overlayed FDG and FDG
alone in the top row and the T2 map, T2 overlayed with 13NH3 and 13NH3 alone in the
bottom row. The FDG image is taken from the last time frame, 57-60 minutes. Very high
FDG uptake is seen within the infarct, meaning high inflammation.
Analysis will include looking at the change in ejection fraction, end-systolic volume and
end-diastolic volume from the first time point to the follow up time-point and determine
if it is affected by the extent of inflammation at the acute time point. Additionally, Patlak
modeling will be done to determine metabolic rate of glucose in infarcted and remote
tissue and extracellular volume will also be measured in both tissues and at both time
points. These values will then be compared with the change in cardiac function from the
initial time-point to the follow-up. 13NH3 imaging provides the additional benefit of
perfusion imaging. As such, the size of the perfusion defect can be compared to the size
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of the metabolically active region determined with FDG PET and also with the size of the
infarct region as determined by T1 mapping. Initial images are shown in figure 5-2.

5.6

Conclusion

This research has advanced the field of hybrid PET/MRI imaging of inflammation postMI in terms of imaging strategies. It is the first work to show that a constant infusion can
be used to penetrate the microvascular obstruction and also the first to show detailed
PET/MRI imaging over the first 6 weeks after myocardial infarction. It is also the first to
show that myocardial glucose suppression with lipid infusion and heparin injection
affects the metabolic rate of glucose in inflammatory cells. This highlights the need for
tracers that do not depend on myocardial glucose suppression.
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